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Abstract 
Smoking is a major preventable risk factor for global morbidity and mortality and is 
influenced by both genetic and environmental factors. With the central goal of understanding 
the links between the complex trait of smoking behavior and genetic as well as epigenetic 
variation in the genome, this thesis focuses on identifying novel associations and validating the 
involvement of candidate genes in smoking behavior. An unbiased, hypothesis-free genome-wide 
scanning approach for association with genetic variants (single nucleotide polymorphisms; SNPs) 
in study I and epigenetic variants (DNA methylation) in study II were applied utilizing biomarkers 
of nicotine metabolism and exposure respectively. Taking a hypothesis-driven targeted 
approach, in study III, the involvement of neuregulin signaling pathway genes in smoking 
behavior was examined and validated in a phenotypically rich family sample. With the increasing 
and due emphasis on interpretation of associations identified in non-protein coding parts of the 
genome, we investigated the regulatory potential of the highlighted variants as well as assessing 
mediation via epigenetic mechanisms, utilizing in-house data and publicly available multi-omics 
resources.  
In study I, utilizing a biomarker for nicotine clearance rate (nicotine metabolite ratio, NMR) 
in a genome-wide association study (GWAS) meta-analysis, we identified novel association on 
chromosome 19, represented by three independent loci mapping to or near the main nicotine 
metabolizing enzyme CYP2A6. We examined the regulatory potential of the SNPs and identified 
a subset of genome-wide significant SNPs (173 of 719) as methylation quantitative trait loci 
(meQTLs). Using causal inference test, we observed methylation at one CpG in DLL3 mediates the 
effect of genotype on NMR. We also constructed a genetic risk score (GRS) with the independent 
SNPs identified in the GWAS meta-analysis, which explain ~30% variance observed in NMR. As 
evidenced by clinical trial studies, NMR influences the efficacy of cessation 
pharmacotherapeutics highlighting the potential value of our findings.  
In study II, we utilized cotinine, an established biomarker of nicotine exposure, and 
performed epigenome-wide association study (EWAS) in regular smokers. We identified several 
novel loci in smoking-related genes, underlining the value of using biological phenotypes. 
Cotinine levels are influenced by nicotine intake as well as nicotine clearance, we utilized the GRS 
constructed in study I to account for such confounding, identifying additional novel loci. We 
further assessed the role of genetic variants in the highlighted genes and identified several cis 
and trans meQTLs. A handful of these meQTLs were also directly associated with cotinine levels. 
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At these loci, we examined whether DNA methylation is a mediator between the observed 
association of genotype and cotinine levels and detected mediation at seven CpG sites, implying 
DNA methylation may be a cause, not a consequence of nicotine exposure, as commonly 
assumed. Our results point at an interplay between the genome and epigenome while identifying 
novel nicotine exposure pertinent loci.  
In study III, we applied a targeted approach to examine the role of the neuregulin signaling 
pathway (NSP) genes in smoking behavior utilizing a phenotypically rich family sample. Extensive 
association and joint linkage and linkage disequilibrium analysis of common, low frequency and 
rare variants in the ten key NSP genes with a wide spectrum of smoking behavior phenotypes 
revealed significant association with seven of the ten genes. No significant associations were 
observed with alcohol use phenotypes hinting at NSP’s involvement specifically in smoking 
instead of addictions in general. Utilizing integrative methods and multi-omics data from an 
independent population sample and publicly available resources, we show the majority (56 of 
66) of highlighted SNPs have regulatory potential. Our results provide evidence for the 
involvement of the NSP in smoking behavior, a candidate pathway for smoking and comorbid 
disorders.  
Key points from this thesis: 
1. Biomarkers can be powerful in identifying meaningful associations even with moderate 
sample sizes in complex behavioral traits.  
2. Genetic and epigenetic differences between individuals influence smoking behavior via genes 
involved in nicotine metabolism, nicotine dependence, and neuronal pathways. 
3. DNA methylation is a molecular mechanism mediating the effects of genotype on smoking 
behavior phenotypes at some loci.  
4. Multi-omics data including, but not limited to, genetics, epigenetics, and transcriptomics can 
immensely aid in assessing the functional consequences of otherwise seemingly non-
functional associations identified via genome-wide association studies providing potentially 
druggable targets for personalized medication.   
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1 Introduction 
All of us are 99.9% genetically identical, yet phenotypically quite different. These differences 
result from not only the small proportion of differences in our genetic code but also from the 
environmental influences on the function of our genome. Influenced by both genes and the 
environment, these interindividual differences hold secrets to many complex diseases that 
burden humanity with morbidity and mortality. As such, a better understanding of the underlying 
mechanisms involved in complex diseases can aid in finding effective treatments. 
Identifying susceptibility genomic loci underlying complex traits using genome-wide 
association analysis has been successful and continues to be the most popular means for 
screening the genome. However, the majority of the identified associations reside in non-coding 
regions of the genome. Unlike the variants located in protein-coding parts of the gene, which 
may alter the amino acid sequence and consequent protein product, variants in non-coding 
regions have an unclear regulatory function. Lately, the focus has shifted towards integration of 
multiple biological data layers (Multiple-omics) such as genetic, epigenomic and transcriptomic, 
to facilitate a more comprehensive understanding of the otherwise seemingly non-functional 
associations.  
This thesis covers association and interplay of genetic and epigenetic variants in the context 
of smoking behavior, a major preventable risk factor of global morbidity and mortality. Genetics 
assessed by single nucleotide polymorphisms (SNPs), epigenetics assessed by DNA methylation, 
as well as transcriptomic data were utilized to further infer functional implications and 
consequences of associations identified. Figure 1 is a pictorial representation of the work 
included in the thesis showing the approaches employed, piecing together the complex biological 
picture of smoking behavior.  
Genome-wide association study (GWAS), a well-established means of identifying genetic 
variants associated with complex traits, was applied in study I to identify genomic regions 
associated with the rate of nicotine metabolism, a major influencer of smoking behavior. For 
instance, to maintain nicotine levels, fast metabolizers smoke more due to quicker clearance of 
nicotine, whereas slow metabolizers smoke less often as nicotine levels are maintained for longer 
from a given intake. Taking a similar hypothesis-free approach to scan the epigenome, an 
epigenome-wide association study (EWAS) was applied to assess the association of serum 
cotinine, a reliable biomarker of nicotine exposure, in study II to identify genomic loci that might 
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influence smoking behavior by epigenetic mechanisms. In study III, hypothesis-driven targeted 
(candidate gene) approach was used to assess the role of neuregulin signaling pathway genes, 
with a wide spectrum of phenotypes encompassing smoking behavior and alcohol use and abuse. 
Figure 1. Methodologies applied in the studies included in this thesis to uncover underlying biology of the 
complex behavioral trait of smoking. 
To uncover the regulatory potential of variants associated with smoking behavior 
phenotypes, integrative analysis using expression and DNA methylation data were employed in 
all three studies. The role of DNA methylation as a molecular mechanism mediating the effects 
of the observed association between genotype and phenotype was also examined in study I and 
II. In the next chapter, literature review covering what is known and what we don’t about the 
genetics and epigenetics of smoking behavior is presented, followed by aims of the three studies. 
Next chapter provides a description of materials and methods employed, followed by the main 
findings and discussion from the three studies. Final chapters present challenges, future 
prospects, and conclusions.  
Literature Review 
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2 Literature Review  
Several factors are involved in the development and progression of human diseases and 
traits. Complex traits influenced by both genes and the environment may be expressed 
differently between individuals. The advancement in technology and reduction in associated 
costs has led to an extensive characterization of the human genome consequently increasing our 
understanding of the underlying biological mechanisms of many complex traits. The contribution 
of genetic factors (quantifiable by the advent of technology) versus environmental factors 
(difficult to quantify) vary across phenotypes and determining a complete picture remains 
challenging. Table 1 provides a glossary of terms that will be used throughout this thesis. 
Table 1. Glossary 
Biomarker A biological identifier characteristic of a disease, pathological or physiological process 
etc. In this thesis, for example, metabolites of nicotine are used as biomarkers of nicotine 
exposure and nicotine metabolism.  
CpG Site in the genome where nucleotide cytosine is adjacent to guanine; DNA methylation 
usually occurs at these sites. 
Epigenome Chemical compounds that overlay the genome and regulate gene activity without 
altering genomic DNA sequence. DNA methylation is the most commonly studied 
epigenetic mark. 
EWAS Epigenome-Wide Association Study; the study of the association between epigenetic 
variation (in this thesis, DNA methylation) to a trait or disease. 
Genome The complete set of genetic information sequence. 
GWAS Genome-Wide Association Study; the study of the association between genetic variation 
(SNPs) in the genome to a trait or disease. 
Omics A wide spectrum of technologies used to explore the roles, relationships, and functions 
of the various biological molecules in an organism. 
Phenotype The trait of interest; set of observed characteristics of an individual arising from the 
interplay between the genome and the environment. For example, behavior, disease 
etc. 
QTL Quantitative Trait Loci; a locus in the genome associated with a quantitative trait 
(molecular measures). For example, gene expression (eQTL) and/or DNA methylation 
(meQTL) 
SNP Single nucleotide polymorphism; variable site in the genome. 
Literature Review 
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2.1 Genetic variation and heritability of traits  
The human genome has more than 3 billion base pairs. Genetic variation such as single 
nucleotide polymorphism (SNPs), insertions, deletions, and copy number variation exists in the 
genome and contribute toward interindividual differences. The most common form of genetic 
variation are the SNPs, occurring at every 300 nucleotides on average, meaning about 10 million 
SNPs exist in the genome. SNPs occur predominantly in the non-coding parts of the genome and 
have variable occurrence (allele frequencies) across populations.  
Twin and family studies have indicated the contribution of genetics to almost every aspect 
of life [1, 2]. This variance observed in a trait attributable to genetics is called heritability [3] and 
has been used as a basis for identifying genomic loci associated with complex traits. One popular 
means of examining the association of a phenotype with genetic variation (SNPs) is genome-wide 
association studies (GWAS). GWAS have been crucial and successful in identifying genetic loci 
targeting a multitude of biological pathways associated with complex traits [4]. The GWAS 
catalog, reporting over 50,000 unique SNP-trait associations (as of September 2017) is a 
testament to the success GWAS approach has seen in the past decade [5]. As such, hypothesis-
free GWAS approach, along with hypothesis-driven candidate gene approach has identified 
genetic susceptibility underlying several complex traits [6, 7]. For instance, in a genetic 
association study of smoking behaviors [8], the chr15q25 region spanning the nicotinic receptor 
genes was identified in a GWAS of smoking quantity. In the same study [8], hypothesis based 
candidate gene approach provided evidence of association in the monoamine oxidases gene, a 
contributor towards reinforcing and motivating effects of smoking [9].  
Trait-associated SNPs identified by GWAS explain less than 50% of estimated heritability 
[10, 11], with a substantial proportion remaining unexplained. Yet, the effect of multiple SNPs 
identified via GWAS summed up into a genetic risk score (GRS), has been used as a measure of 
genetic susceptibility and holds great utility, as a proxy for the trait in different samples [12, 13]. 
Common and low-frequency variants explain a fairly small proportion of the genetic contribution 
to variance observed in common traits [14]. It has been long speculated that rare variants (with 
large effects) and other structural variations (insertions, deletions, and copy number variation), 
variants not tagged by the arrays, non-additive genetic effects, and gene-environment 
interactions may explain some of the missing heritability [15]. Rare variant effects can be 
captured using family samples and population isolates [16], while sequencing technology can 
help identify variants undetectable by microarrays, adding additional information toward missing 
Literature Review 
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heritability. Lately, epigenetics has also come to focus and is considered a valuable contributor 
toward missing heritability [17].  
2.2 Epigenetics and its contributions in trait variation 
Epigenetics, as defined in Table 1, refers to a set of chemical modifications that play a key 
role in regulating gene expression by altering DNA accessibility and chromatin structure [18, 19]. 
Epigenetic mechanisms include DNA (methylation) and histone modifications (methylation and 
acetylation), as well as regulation by non-coding RNAs [20]. High-risk genetic variants identified 
in association studies reside in regulatory regions of the genes [21] which are the main sites of 
epigenetic regulation. Therefore, mapping epigenetic changes may shed some light on the 
missing heritability. The human epigenome has been intensively studied in the last decade, with 
large-scale projects like the Roadmap, ENCODE and blueprint projects [22-24] mapping 
regulatory features across the genome. Most commonly studied epigenetic alteration is DNA 
methylation (referred to as methylation here on in the thesis), wherein a methyl group is 
attached to cytosine of cytosine-guanine dinucleotides (CpG site; Table 1) or non-CpG sites such 
as CHG or CHH (where H correspond to A, T or C). However, methylation is almost exclusively 
found in CpG dinucleotides. This dynamic epigenomic feature is tissue and cell type specific and 
is influenced by environmental factors like age and lifestyle (for example - diet, smoking, and 
drinking habits). Aside from these factors, methylation variation is also largely driven by genetic 
variation [25]. Although conventionally viewed as a transcriptional repressor, methylation has 
been associated with increased transcriptional activity as well [19] and is one of the mechanisms 
by which gene expression is regulated. Like GWAS, unbiased screening of the epigenome with 
epigenome-wide association studies (EWAS) is gaining importance in identifying novel disease-
associated genomic loci that may be under epigenetic regulation and are not discovered through 
genetic studies [26].  
2.3 Regulatory potential of trait-associated variants 
As mentioned above, association studies have been successful in identifying genomic 
regions associated with complex traits and diseases. However, it is difficult to figure out the 
causative variant underlying each association signal and its effect in most cases. Most of the 
genetic associations identified in GWAS, not surprisingly, reside in the non-coding region of the 
genome. Unlike variants in the protein-coding parts of the genome, where the genetic variation 
may function by altering the final protein product of the gene, variants in the non-coding parts 
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of the genome can pose difficulty in inferring their functional role. Regulatory potential of such 
variants has taken the focus of current research [27-31].  
There is growing evidence for the contribution of genetic variants toward gene expression 
and methylation patterns [32]. Trait-associated variations in the DNA sequence could affect gene 
function via alteration of expression or methylation, or any other epigenetic mechanism. A 
genetic locus that affects a molecular trait such as gene expression, methylation or histone 
modifications, is called a quantitative trait loci (QTL). Figure 2 illustrates how molecular data 
layers, such as epigenetic and transcriptomic, can be useful in identifying the mechanistic role of 
the variants identified by genetic association studies, providing greater insight into the 
consequential effects of such variants [33]. These hereditary traits also provide a plausible 
mechanism by which methylation and expression patterns could be different under 
environmental exposures. 
Figure 2. Molecular data including the genetic sequence, gene expression and methylation from the tissue 
of interest once obtained, can be utilized to assess whether the genetic variants are quantitative trait loci 
(QTL). An observed association between the genotype and molecular traits such as expression (eQTL) and 
DNA methylation (meQTL) may explain how the trait associated genetic variants may regulate the 
phenotype of interest.    
The QTLs provide valuable information on whether or how the genetic variation may be 
regulating gene function. It would be of further interest to explore mediation via therapeutically 
targetable mediators, for example, methylation. With multiple layers of biological data (multi-
omics; see section 2.4 below), mediation via molecular mechanisms between trait and genotype 
can be tested using statistical frameworks such as causal inference test and Mendelian 
randomization [34, 35]. This is tremendously useful in identifying mediators which provide 
additional targets for therapeutic intervention.  
Literature Review 
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Integration of multiple layers of biological data can bring more information than analysis 
of single layers alone. The ability to combine multiple layers of molecular data with each other 
will allow uncovering further systemic information regarding biological modifications that occur 
in complex traits. The application of this approach has the potential of identifying targets for 
therapeutic interventions. 
2.4 The era of omics - quantifiable biological data  
Omics, referring to different layers of biological data aims at exploring the functions of as 
many genes as possible. The advancement in technology, especially the low-cost microarray, has 
powered tremendous progress in genomic research. Figure 3, provides an overview of the 
workflow of a microarray. The basic workflow remains unvarying across different omics data 
generated by microarray with differences present in sample preparation and array designs 
(oligobeads versus features spotted on to the array).  
Figure 3. This figure represents a general workflow of microarray chip technology with differences present 
at each step between genotype, DNA methylation, and gene expression array designs and chemistry.  
Large-scale sequencing projects such as the 1000 genomes [36], HapMap [37], and 
Haplotype Reference Consortium [38] have enabled cost-effective genotyping of individuals on 
large-scale. For example, genotyping can be performed with SNP microarray that tags only a 
handful of SNPs and genomic reference panels based on the large-scale sequencing projects can 
then be used for imputation of unobserved (not directly genotyped) variants providing a broad 
view of the genome. In capturing methylation using microarray a key step is bisulfite conversion. 
Treating denatured DNA with sodium bisulfite helps in distinguishing methylated versus 
unmethylated cytosine. Bisulfite conversion leads to deamination of unmethylated cytosine 
residues to uracil, leaving methylated cytosine intact. The uracil is subsequently amplified to 
thymine and detection of cytosine and thymine, like in genotyping arrays, depicts the 
methylation status at a CpG site. For measuring the expression of genes, messenger RNA isolated 
from the samples is labeled with fluorescent dye and reverse transcribed to generate 
Sample 
preparation -
Fluorescent 
labelling
Hydridization 
with 
oligobeads/prob
es on microarray
Flourescence 
scanning -
Raw intensity 
data produced 
Data processing -
Quality checks 
Normalization
Analysis
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complementary DNA sequence which is hybridized to the microarray. The fluorescence measure 
reveals the relative expression of genes across samples. 
With the early development and popularity of microarray technology, standard protocols 
for data processing are well established for genotyping and gene expression analysis. However, 
methylation arrays being relatively new and owing to a different design - two types of probes on 
the same array (Infinium Human Methylation 450K and EPIC arrays), still lack consensus on a 
standard protocol for data processing. Numerous pre-processing and normalization methods for 
methylation array have been implemented and comprehensively reviewed [39-48]. With each 
method having limitations and advantages, a consensus has been difficult to reach [49]. Quantile 
normalization is performed to transform all the arrays to have a common distribution of 
intensities [50]. However, the two-probe biochemistry, although greatly increases genomic 
coverage, necessitated further within-array normalization methods to be developed such as 
Beta-mixture quantile dilation [51], Subset-quantile within array [52] and dasen [47], which allow 
the signals from both probe types to be analyzed together. Other normalization methods such as 
Stratified quantile normalization [53] took into consideration the genomic localization of probes 
to adjust for technical variation. In a recent study by Lehne et al. [54], quantile normalization of 
raw intensity values categorized by probe type, color channel, and probe subtypes (similar in 
concept to functional normalization [55]) outperformed existing normalization methods and is 
gaining acceptance even for large-scale consortia analysis.  
2.5 Smoking behavior  
Among environmental factors that adversely affect the health is tobacco smoking, a major 
avoidable source of mortality across the globe [56]. Smoking is a risk factor for dire diseases like 
cancer, cardiovascular and respiratory disorders [57]. Smoking behavior is a complex phenotype 
entailing different aspects including, but not limited to, smoking initiation, nicotine dependence, 
nicotine withdrawal, and cessation [12]. There are several factors that influence smoking 
initiation, for example, peer pressure in adolescence [58], gender, familial conditions 
(socioeconomic status and habits of other members), ethnicity, and other substance use [59-61]. 
Not all individuals who initiate smoking develop nicotine dependence. However, smokers who 
develop nicotine dependence due to persistent smoking might find it difficult to quit despite 
knowing the adverse consequences. Nicotine, the addictive component of cigarette, has a 
positive reinforcing effect and is one of the key factors determining smoking cessation success 
[57]. Nicotine withdrawal symptoms such as anxiety, irritability, concentration problems, 
Literature Review 
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depressed mood, and cravings make abstinence difficult consequently resulting in high relapse 
rates [62, 63]. Different aspects of smoking behavior can be captured with self-report 
questionnaires, objective assessment measures such as the Diagnostic and Statistical Manual of 
Mental Disorders (DSM) [64] and the Fagerström Test of Nicotine Dependence (FTND) [65] and 
biochemical measures such as cotinine levels in urine, saliva or serum can quantify nicotine 
exposure [66]. It is worth noting that each form of measure taps somewhat overlapping yet 
distinct domains of smoking behavior. For instance, DSM-IV based diagnosis and FTND are both 
measures of nicotine dependence, however, FTND is more reflective of smoking heaviness 
(higher correlation with both self-report and biochemical measures) and cessation likelihood 
than DSM based nicotine dependence [67].  
Nicotine metabolism. One of the key drivers of nicotine dependence is the addictive potential of 
nicotine, hence understanding the mechanisms involved in nicotine breakdown in the body are 
of great importance. Nicotine is metabolized mainly by cytochrome P450 oxidases (primarily 
CYP2A6) in the liver [68], with ~75% of nicotine being converted to cotinine, which is further 
metabolized to trans 3-hyrdoxycotinine [69]. The ratio of 3-hydroxycotinine to cotinine, called 
the nicotine metabolite ratio (NMR), is an established biomarker of CYP2A6 activity and can be 
used as a proxy for nicotine clearance rate. NMR critically affects smoking behavior, for example, 
individuals with faster nicotine metabolism tend to smoke more in order to self-titrate [70], 
putting them at higher risk of developing smoking-associated diseases [71]. On the other hand, 
individuals with slower metabolism tend to smoke less often as nicotine from a given intake is 
maintained for longer in their body. Such difference affects how much and how often a person 
smokes.  
Cotinine, the primary metabolite of nicotine, has a long half-life (15–20 hours) [66] and is a 
reliable indicator of recent nicotine exposure, making it superior to the self-reported smoking 
quantity which is error-prone due to misreporting and recall bias. Cotinine levels are affected by 
nicotine intake i.e. how much a person smokes. In addition, it is also influenced by the rate of 
nicotine metabolism i.e. formation of cotinine from nicotine as well as clearance of cotinine 
(converted to trans 3-hydroxycotinine). This metabolism is largely mediated by CYP2A6 and can 
be measured with NMR. As described above, NMR also affects smoking behavior by altering 
nicotine intake, making its influence on cotinine levels more prominent. Metabolites have been 
highly successful in identifying genetic susceptibility loci [72, 73] as they provide biological 
proximity as well measurement precision. Biomarkers such as cotinine and NMR provide great 
Literature Review 
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statistical power in association studies [74, 75]. In a GWAS meta-analysis of cotinine [74], aside 
from the most consistently identified genome-wide significant locus associated with smoking i.e. 
nicotinic receptor gene cluster, a locus on chromosome 4 encompassing UGT2B10 gene was 
identified. This gene although involved in nicotine and cotinine metabolism [76] was not 
associated with smoking quantity [74], indicating that cotinine captures more than mere nicotine 
exposure. This is in line with the factors that influence cotinine levels described above.  
Comorbidities. Smoking is highly comorbid with other behavioral phenotypes, the most 
prominent one being alcohol use [77]. Smoking is also associated with several neuropsychiatric 
disorders [78-80]. One such disorder is schizophrenia (SCZ), where one hypothesis is that the 
diseased tend to smoke more in order to self-medicate [81]. Such comorbidities further 
complicate smoking cessation. Many cessation pharmacotherapies such as nicotine replacement 
therapy, bupropion, and varenicline are available but show a maximum of two to three-fold 
success rate [82]. There is a high demand for smoking cessation therapeutics to aid smokers 
trying to quit as well as target comorbid illnesses.  
2.5.1 Genetics of smoking 
Smoking behavior is a multifactorial trait with substantial genetic influence [83], and its 
genetic contribution has been well reviewed [84, 85]. Heritability estimates vary across different 
aspects of smoking behavior and ranges between 35% - 55% for smoking initiation [86, 87], 31% 
- 75% for nicotine dependence  [86, 88-90], 26%-50% for nicotine withdrawal [91-94] and have 
been reported as high as 81% for rate of nicotine metabolism [75, 95, 96]. In 2010, three large-
scale GWAS meta-analysis (N~140,000) identified genome-wide significant loci underpinning 
different stages of smoking [97]. Associations highlighted the role of brain-derived neurotrophic 
factor gene (BDNF) in smoking initiation [98], nicotinic receptor gene cluster (CHRNA5–CHRNA3–
CHRNB4) [98, 99] and CYP2A6 in smoking dependence [100], and dopamine β-hydroxylase (DBH) 
gene with smoking cessation [98, 101]. Numerous other genetic studies have identified many 
other genetic loci associated with different aspects of smoking.  
Nicotine Metabolite Ratio. As described above, NMR is a key influencer of smoking behavior and 
varies significantly between individuals [102, 103] with high heritability estimates (~80%), 
suggesting major genetic contribution to the variance observed in NMR [75]. Clinical trial studies 
stratifying participants on their NMR profiles indicated its influential role in the efficacy of 
smoking cessation pharmacotherapies [104, 105]. It is worth noting that only a fraction of 
interindividual differences in nicotine metabolism is accounted for by known reduced activity 
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CYP2A6 variants (www.pharmvar.org/htdocs/archive/cyp2a6.htm) [106] and up to 85% remains 
unexplained [107]. GWAS in different population samples have identified population-specific 
variants associated with NMR [75, 108, 109].  
In addition to the genes identified by hypothesis-free screening of the genome, the role 
of pathways and candidate genes in distinct and overlapping stages of smoking progression has 
become evident [110, 111]. One such set of candidate genes comprise the main functional 
components of the neuregulin signaling pathway (NSP).  
Neuregulin signaling pathway. The NSP, a modulator of neuronal migration and differentiation 
has ten key functional components presented as a protein-protein interaction (PPI) network in 
Figure 4. Table 2 further provides the functions of the ten genes. The NSP has been implicated in 
nicotine dependence and associated psychiatric comorbidities [112].  
Figure 4. The neuregulin signaling pathway as a protein-protein interaction (PPI) network. The key 
components of the NSP include the neuregulin signaling molecules (NRG1 and NRG3), their receptor 
(ERBB4), beta-secretase (BACE1) and gamma-secretase complex (PSEN1, PSEN2, APH1A, APH1B, PSENEN, 
and NCSTN). Modified figure produced using string-db.org [113], a PPI network database. 
Literature Review 
12 
 
Table 2. Summary of the ten key genes comprising the neuregulin signaling pathway. Gene summaries 
derived from STRING database [113] in conjunction with Figure 4. 
Gene Chr Function 
Neuregulins 
NRG1 8 Neuregulin 1; Direct ligand ERBB4 tyrosine kinase receptors. Concomitantly recruits ERBB1 and 
ERBB2 coreceptors, resulting in ligand-stimulated tyrosine phosphorylation and activation of the 
ERBB receptors. The multiple isoforms perform diverse functions such as inducing growth and 
differentiation of epithelial, glial, neuronal, and skeletal muscle cells; inducing expression of 
acetylcholine receptor in synaptic vesicles during the formation of the neuromuscular junction. 
NRG3 10 Neuregulin 3; Direct ligand for the ERBB4 tyrosine kinase receptor. Binding results in ligand-
stimulated tyrosine phosphorylation and activation of the receptor. 
Neuregulin receptor 
ERBB4 2 V-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian); Tyrosine-protein kinase that 
plays an essential role as cell surface receptor for neuregulins and EGF family members and 
regulates development of the heart, the central nervous system and the mammary gland, gene 
transcription, cell proliferation, differentiation, migration and apoptosis 
Beta secretase 
BACE1 11 Beta-site APP-cleaving enzyme 1; Responsible for the proteolytic processing of the amyloid 
precursor protein (APP). Cleaves at the N-terminus of the A-beta peptide sequence, leads to the 
generation and extracellular release of beta-cleaved soluble APP, and a corresponding cell-
associated C-terminal fragment which is later released by gamma-secretase 
Gamma secretase complex 
APH1A 1 Anterior pharynx defective 1 homolog A; Essential subunit of the gamma-secretase complex, an 
endoprotease complex that catalyzes the intramembrane cleavage of integral proteins. It 
probably represents a stabilizing cofactor for the presenilin homodimer that promotes the 
formation of a stable complex 
NCSTN 1 Nicastrin; Essential subunit of the gamma-secretase complex, an endoprotease complex that 
catalyzes the intramembrane cleavage of integral membrane proteins. It probably represents a 
stabilizing cofactor required for the assembly of the gamma-secretase complex 
PSEN2 1 Presenilin 2; Probable catalytic subunit of the gamma-secretase complex, an endoprotease 
complex that catalyzes the intramembrane cleavage of integral membrane proteins. Requires the 
other members of the gamma-secretase complex to have a protease activity. May play a role in 
intracellular signaling and gene expression or in linking chromatin to the nuclear membrane and 
may function in the cytoplasmic partitioning of proteins 
PSEN1 14 Presenilin 1; Probable catalytic subunit of the gamma-secretase complex, an endoprotease 
complex that catalyzes the intramembrane cleavage of integral membrane proteins. Requires the 
other members of the gamma-secretase complex to have a protease activity. May play a role in 
intracellular signaling and gene expression or in linking chromatin to the nuclear membrane.  
APH1B 15 Anterior pharynx defective 1 homolog B; Probable subunit of the gamma-secretase complex, an 
endoprotease complex that catalyzes the intramembrane cleavage of integral proteins. It 
probably represents a stabilizing cofactor for the presenilin homodimer that promotes the 
formation of a stable complex. Probably present in a minority of gamma-secretase complexes 
compared to APH1A 
PSENEN 19 Presenilin enhancer 2 homolog; Essential subunit of the gamma-secretase complex, an 
endoprotease complex that catalyzes the intramembrane cleavage of integral membrane 
proteins. Probably represents the last step of maturation of gamma-secretase, facilitating 
endoproteolysis of presenilin and conferring gamma-secretase activity 
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One of the potential mechanisms by which NSP may be involved in nicotine dependence 
is through modulation of nicotinic acetylcholine receptor expression, which can be induced by 
binding of nicotine causing a cascading effect of conformational changes resulting in increased 
expression of NRG3 [112]. The NRG3 can be proteolytically cleaved by BACE1 (beta-secretase) 
and bind to the ERBB4 receptor or alternatively, NRG3 may be cleaved by a gamma-secretase 
complex and can subsequently regulate gene transcription. The signaling molecule NRG3 and its 
receptor ERBB4 are associated with smoking initiation, nicotine dependence, and nicotine 
withdrawal symptoms in human and behavioral mouse model studies [114-116]. NRG1 has been 
robustly associated with schizophrenia, a neurodevelopmental disorder with extremely high co-
occurrence with smoking and nicotine dependence [81, 117]. Further, deficiency of BACE1 or 
APH1B is reported to cause neurobehavioral abnormalities like schizophrenia in mice [118, 119]. 
Underlying genetic factors common to psychiatric disorders and smoking, make NSP a prime 
candidate for exploring the therapeutic potential to treat comorbidity observed between 
smoking, other substance use as well as psychiatric illness. 
2.5.2 Epigenetics of smoking 
Smoking has a major influence on methylation changes across the genome, as evidenced 
by numerous EWAS conducted in last few years and has been extensively reviewed [120, 121]. 
To highlight the incredible amount of evidence supporting the prominent effect of smoking on 
methylation, Table 3 summarizes the findings from EWAS conducted in healthy adults using 
methylation profiled in peripheral blood thus far (September 2017).  
Table 3. Table summarizing the findings from EWAS studies conducted in methylation profile of peripheral 
blood from healthy adults in chronological order.  
Reference Assay* Sample 
Size 
Summary 
Breitling et al. [122] 
 
27k 177 First study examining genome-wide methylation in context of smoking in 
Caucasians. Only one CpG cg03636183 in F2RL3 identified. 
Wan et al. [123] 27k 1085 Two loci in F2RL3 and GPR15 identified. Authors suggested methylation 
responds to change in smoking behavior. 
Siedlinski et al. [124] Golden 
Gate 
316 Only one CpG site in the TGFBI gene was associated with ever-smoking after 
adjusting for age and sex.  
Shenker et al. [125] 450k 374 First report of association at AHRR with smoking exposure among other 
novel loci. 
Philibert et al. [126] 450k 399 Association at AHRR locus even with low levels of smoking (less than half a 
pack-year) in a sample of young African Americans (average age 19 years) 
Sun et al. [127] 27K 972 Loci in F2RL3 and GPR15 replicated in African Americans, consistent with 
findings in Caucasians 
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Zeilinger et al. [128] 450k 1793 Widespread effects of smoking observed in all chromosomes, with 
methylation at a few CpGs explaining upto 41% variance. Authors also 
suggested reversal of methylation levels upon smoking cessation. 
Philibert et al. [129] 450k 107 First study using serum cotinine in a sample of young African American 
men. Only 2 CpG sites identified in AHRR. 
Besingi et al. [130] 450k 432 Reported that methylation changes are caused by burnt products of 
tobacco based on their observation of no significant association between 
methylation and snuff (smokeless tobacco). 
Elliot et al. [131] 450k 192 Reported ethnic differences (Europeans vs South Asians) in smoking 
associated methylation patterns. Authors also constructed a smoking score 
for prediction of smoking status. 
Dogan et al. [132] 450k 111 Identified close to 1000 CpG sites associated with smoking in African 
American women.  
Tsaprouni et al. 
[133] 
450k 464 First report of a meQTL (rs2697768), affecting methylation levels at 
smoking associated cg03329539. Authors also reported this meQTL 
regulates expression of the CHRND (Cholinergic Receptor Nicotinic Delta 
Subunit) gene and that methylation levels are reversible upon cessation. 
Flanagan et al. [134] 450k 92 Reported methylation pattern at the 2q37.1 and AHRR loci are stable over 
time as well as associated with time since quitting. 
Guida et al. [135] 450k 745 Conducted in an all women population sample (European), the authors 
reported two types of CpG methylation patterns: ones that revert to levels 
of never smokers in less than a decade while others that do not, even after 
35 years of smoking cessation.  
Zaghlool et al. [136] 450k 123 The first study in Arab population, replicating findings from previous studies 
in Caucasians. 
Allione et al. [137] 450k 40 Using a discordant twin pair design, the authors reported associations 
between methylation and smoking that are free of genetic confounding. 
Qiu et al. [138] 27k 85 Examined association of CpG methylation with smoking and genetic 
variation in the vicinity of the highlighted CpG sites identifying meQTLs. 
Sergi-Baixeras et al. 
[139] 
450k 645 Among several other replicated loci, novel association was reported at a 
CpG site (cg06394460) in a smoking-associated gene LNX2. 
Zhang et al. [140] 450k 500 Cotinine was used as a biomarker in EWAS. Authors also examined the use 
of methylation vs cotinine in distinguishing current from former and never 
smokers and reported methylation as a better measure.  
Ambatipudi et al. 
[141] 
450k 910 Identified several smoking associated loci and reported reversion of 
methylation levels at a subset of CpG sites upon cessation, while another 
subset of CpG sites did not respond to cessation even after 22 years like 
previously suggested by Guida et al. [135] 
Joehanes et al. [142] 450k 15,907 First large meta-analysis including 16 cohorts identified methylation at 
~7000 CpG sites related to smoking. 
Lee et al. [143] 450k 100 First EWAS in the Korean population. Current smokers were verified using 
cotinine measures, however, cotinine levels were not used as a phenotype. 
Authors also report the association of gene expression in lung tissue with 
the top CpG sites.  
Dogan et al. [144] 450k 1599 Authors report both distal and proximal interactions between genetic 
variants and smoking associated methylation; suggesting integrative 
analysis of epigenetic and genetic data is pivotal for a comprehensive 
understanding of the relationship between smoking and the genome. 
* Methylation assessment platform used in each study.  
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The most prominent associations observed consistently are in the aryl hydrocarbon receptor 
repressor (AHRR) and F2R Like Thrombin/Trypsin Receptor 3 (F2RL3) genes. AHRR, a key regulator 
of the relationships between the cell and the external environment, is involved in the xenobiotic 
metabolism such as polycyclic aromatic hydrocarbons (toxic components of cigarette smoke) 
[145]. F2RL3 encodes the protease-activated receptor-4 which is likely involved in the 
pathophysiology of both cardiovascular and neoplastic diseases [146].  
Methylation is tissue and cell-type specific. Although other smoking pertinent tissues such 
as buccal cells [147] and lungs [148] have also been studied, blood remains the primary tissue of 
choice because of the availability and accessibility. It should be noted that the methylation 
signature of smoking between buccal cells and blood although generally match for top ranking 
CpG sites, there was a ~40-fold higher association signal observed in buccal cells [147]. It is 
noteworthy that almost all the EWAS on smoking have utilized error-prone (misreporting or recall 
bias) self-reported measure of smoking, and the scope for utilizing a reliable source, such as a 
biomarker – Cotinine, would be valuable in capturing the direct effect of nicotine exposure on 
methylation. Smoking-related cardiovascular diseases [149, 150], cancer [151, 152], as well as 
maternal smoking during pregnancy and aberrant methylation in offspring [153] have also been 
extensively studied, implicating a wide-spread effect of smoking on the epigenome throughout 
the life course.   
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3 Aims 
The focus of the work included in the thesis was to examine the association and interplay 
between genetic (SNPs) and epigenetic (DNA methylation) variants using hypothesis-free and 
hypothesis-driven approaches in smoking behavior. Specific aims for each of the studies included 
are listed below: 
I. Identify novel genetic variants associated with the rate of nicotine metabolism using a 
biomarker and assess their functional consequences via epigenetic mechanisms.  
II. Identify DNA methylation signature of nicotine exposure using serum cotinine levels in 
regular smokers. Investigate genetic contribution to the observed associations as well as 
assess whether methylation changes are a cause or consequence of nicotine exposure. 
III. Validate the role of neuregulin signaling pathway genes in smoking behavior as opposed 
to addiction in general while examining the functional potential of the associating genetic 
variants using multi-omics data.  
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4 Materials and Methods 
4.1 Study samples 
In all three studies, data from Finnish population was analyzed. For replication of findings and 
functional annotation, publicly available data resources were utilized as detailed later in this 
section. Table 4 provides information on the samples and corresponding omics data analyzed 
within each cohort and study. 
The Finnish Twin Cohort (Study I, II & III) 
The Finnish twin cohort (FTC), was established in 1974 with the aim of studying genetic and 
environmental factors impacting complex diseases and associated behavioral risks. The FTC [154] 
has three main data sets including the Older Finnish Twins, FinnTwin16, and FinnTwin12, 
overviewed below:  
1) Older Finnish Twins (Study I, II & III). Same-sex twin pairs (both monozygotic and dizygotic [155]) 
born before 1958 were identified from central population register data and surveyed in 1975 to 
form the Older Finnish Twin Cohort. Opposite sex pairs born 1938-1949 were included to expand 
the cohort in 1996. Follow-up data collection took place in 1981, 1990 and 2011-2012 [154, 156]. 
Several sub-studies concentrating on specific phenotypes such as nicotine dependence, alcohol 
addiction, and hypertension were more intensively studied (biological and clinical samples were 
collected from the participants) and are described below:  
NAG-FIN (Study I, III). Twins concordant for current smoking based on the questionnaire 
data were selected and recruited along with their family members (mostly siblings) to 
establish a family study designed to address genetics of nicotine dependence as part of an 
international consortium - Nicotine Addiction Genetics (NAG-FIN) [114, 157]. Data was 
collected in 2001-2005 and included a self-report questionnaire, diagnostic telephonic 
interview, and blood sample for DNA extraction. Information on lifetime smoking behavior 
aspects (including initiation, quantity, cessation, withdrawal symptoms, alcohol use and 
psychiatric comorbidities) were collected to extensively capture the complex landscape of 
addiction behaviors.  
Schizophrenia twin cohort (Study III). The SCZ twin cohort [158, 159] comprises of same-
sex (both monozygotic and dizygotic) twin pairs discordant for schizophrenia diagnosis 
based on the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) 
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criteria [160]. From this sub-study, 18 schizophrenia cases, and 55 controls (18 co-twins, 
and 37 control twins) had blood samples drawn and corresponding gene expression data 
available (N = 73).  
EH-Epi (Study II). To study hypertension, individuals with diagnosed hypertension, use of 
anti-hypertensive medications and a history of blood pressure measurements were 
selected. These individuals were interviewed, examined and subjected to blood draws in 
2012-2014. Methylation data from individuals (N=55) within this sub-study was available 
and utilized in study II.  
2) FinnTwin16 (Study I & II).  Initiated in 1991, FinnTwin16 is a longitudinal study comprising twins 
born during 1975-1979, first assessed at age 16 along with their parents. Follow-up data 
collection was done at ages 17, 18.5 and 24 [157] with a fifth wave of follow-up done in 2011 
[154]. This study in younger twins was aimed at examining behavioral risk factors at an early age 
and later disease outcome. Along with self-report questionnaires and neuropsychological tests, 
blood samples for DNA extraction and serum metabolite measurements were also collected. For 
a subset of these twins who participated in sub-studies focusing on alcohol (Alcohol study, N=54) 
and obesity (TwinFat, N=14) research, methylation data was produced during the 4th wave of 
data collection and these samples were used in study II. 
Alcohol study. This sub-study within the FinnTwin16 was designed to study the effects of 
alcohol on brain [161]. Twin pairs concordant and discordant for alcohol use were 
selected based on the self-report questionnaire data from 2000-2002 follow-ups.  
TwinFat. This sub-study was based on individuals from FinnTwin12 and FinnTwin16 (see 
below) which were selected to study obesity in twins. These twins completed an intensive 
metabolic study protocol [162] and assessment of behavioral traits (questionnaires, 
interviews, and diaries) in 2002-2013.  
3) FinnTwin12 (Study I & II). Initiated in 1994, FinnTwin12 is a longitudinal study comprising twins 
born during 1983-1987, first assessed at age 11–12 along with their parents and teachers to study 
the precursors of health-related behaviors, especially use and abuse of alcohol [163]. Follow-up 
data collection were done at ages 14, 17.5 years and 22 [157, 163]. Data collection included 
structured psychiatric interviews and blood for DNA extraction. Methylation and serum 
metabolite measurements for N=189 individuals from FinnTwin12 were available and included in 
the analysis for study II.  
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Table 4. Samples included in the three studies and their characteristics. 
Study  Cohort Age (Mean, 
Range, SD) 
% 
Males 
BMI (Mean, 
Range, SD) 
Genotype Methylation Expression 
I FTC 24 (21-30, 2.0) 50 24 (16-43, 4.0) 385 171 - 
 
FINRISK2007 49 (25-74, 12.8) 54 27 (16-50, 5.0) 419 - - 
 
YFS 30 (15-45, 8.6) 54 24 (16-46, 3.9) 714 - - 
II FTC 30 (21-68, 14.2) 48 24 (16-42, 4.4) 304 310 - 
III NAG-FIN 56 (30-92, 10.1) 52 - 1998 - - 
 
DILGOM 52 (25-74, 13.7) 46 27 (16-47, 4.7) 512 512 512 
 
SCZ 45 (24-57, 8.3) 30 - - - 73 
SD: Standard deviation; BMI: Body Mass Index 
In addition to the FTC, additional cohorts from Finland were included in study I for GWAS meta-
analysis and in study III for functional annotation: 
The Young Finns Study (Study I). With first data collection in 1980, the Young Finn Study (YFS) is 
a follow-up study of cardiovascular risk factors from childhood to adulthood [164]. The follow-up 
was done at 3, 6, 9, 12, 21, 27, and 30 years, with wide-ranging risk factor assessments, including 
smoking status and alcohol use. A total of 714 current smokers were included in study I for meta-
analyses having both genotype and metabolite measurements available from 2001 follow-up 
when the average age of participants was 21 years.   
FINRISK (Study I). Finnish adult population survey-based studies conducted every five years since 
1972 assessing risk factors of chronic diseases [165]. At the end of 2006, adults (age 25-74) who 
had ever smoked, were given a smoking-specific questionnaire as a part of FINRISK survey in 
2007. A total of 419 biochemically (cotinine level>10ng/ml) verified current smokers were 
included in study I meta-analyses. A larger non-overlapping sample (N=19,857) from the FINRISK 
cohorts (1992, 1997, 2002 and 2007) was additionally utilized in examining the linkage 
disequilibrium (LD) patterns and allele frequencies, and for prediction analysis of the GRS in study 
I. Metabolite values were not available in this larger sample. 
DILGOM (Study III). DIetary, Lifestyle and Genetic determinants of Obesity and Metabolic 
syndrome (DILGOM) is a sub-study within FINRISK2007. It is a cross-sectional population 
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study designed to examine the effects of lifestyle factors (such as diet and exercise), 
environment, and genetics on obesity and metabolic syndrome [166, 167]. Data collection 
was done in 2007 which included self-report questionnaires as well as blood samples. For 
N=512 individuals, genome-wide genotype, gene expression and DNA methylation data 
generated at the same time point were available, making it a valuable multi-omics dataset.   
Ethical permissions for all the cohorts have been approved by appropriate ethics committees and 
have been submitted to the Faculty of Medicine, University of Helsinki in conjunction with this 
thesis.  
4.2 Phenotypes 
The aim of the thesis was to dissect the genetics and epigenetics of smoking behavior. Across the 
three studies, a wide range of phenotypes capturing smoking behavior and associated 
comorbidities were tested. Table 5 provides a summary of the phenotypes tested segregated into 
three wide categories:  
Biomarkers/Metabolites. The metabolites - cotinine and trans 3-hydroxycotinine are the 
metabolized products of nicotine. These were measured from the serum using liquid 
chromatography-tandem mass spectrometry at the University of Toronto, Canada (Prof. Rachel 
Tyndale’s lab) and at the National Institute for Health and Welfare, Helsinki, Finland [168]. For a 
subset of the sample used in study III (N=68), cotinine measurements were done at the 
Metabolomics unit at Institute for Molecular Medicine Finland (FIMM), University of Helsinki, 
Finland [169, 170]. The ratio of trans 3-hydroxycotinine to cotinine (NMR) was used in study I, 
whereas cotinine (nanogram per milliliter; ng/ml) was used in study II. The NMR values were rank 
transformed to achieve near-normal distribution as it was used as the dependent variable in the 
analyses. Rank transformation was performed using function ‘rntransform’ in R package GenABEL 
[171] which sets the median value as zero and transforms all values centering the normal 
distribution around it. In study I, a threshold of cotinine ≥ 10 ng/ml was applied to select current 
regular smokers, whereas in study II a lower threshold of cotinine ≥ 4.85 ng/ml was applied. The 
lower threshold of cotinine has previously been suggested as an appropriate cut-off to identify 
current smokers in Caucasians [172]. This was used to maximize the sample size (methylation 
data available) for analysis. To ensure using a lower threshold did not affect the results heavily, 
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we performed sensitivity analysis using the threshold of cotinine>10ng/ml (N=293) and observed 
negligible differences (Appendix I).  
Self-reported smoking. Questionnaire-based data for the self-reported smoking and alcohol use 
was available from the NAG-FIN cohort. Detailed self-reported smoking status was available from 
DILGOM cohort [173] categorized as current daily smokers (N=84), current occasional smokers 
(N=34), recent quitters (1-6 months of abstinence) (N=13), former smokers (>6 months of 
abstinence) (N=133) and never smokers (N=245). NAG-FIN and DILGOM cohorts are valuable 
resources, particularly for the work included in this thesis, as they provide a comprehensive view 
of smoking behavior. The smoking phenotypes analyzed were adapted from Broms et al. [174] 
and are listed in Table 5. In the statistical analysis, cigarettes per day (CPD) was used as class 
means of CPD (1.5, 3.5, 8, 13, 17.5, 22.5, 32.5, and 45 CPD, respectively) such that the regression 
coefficients can be interpreted as the average change in number of cigarettes smoked per day 
when the number of minor alleles is increased by one. Even though quantitative phenotypes 
provide higher statistical power than binary phenotypes [175], in study III, the quantitative 
variables were converted to binary variables (see Table 5 for definitions) to accommodate the 
data for joint linkage and LD analysis and rare variant association analysis (see section 4.4.1.1). 
The cut-off of 3 or 4 was based on the number of criteria needed to make a diagnosis as specified 
in the DSM-IV manual and the manual for the semi-structured assessment for the genetics of 
alcoholism [176] and nicotine addiction genetics [177] interviews.  
Smoking associated comorbidities. In study III, to examine the involvement of NSP specifically in 
smoking, we utilized the self-reported data on alcohol use and abuse in the NAG-FIN sample. 
Since SCZ and smoking are also highly comorbid, we utilized the SCZ twin sample to examine the 
confounding effect of smoking on the NSP gene expression between SCZ and controls. 
Covariates. In all studies, relevant covariates were included in the regression models. Age and 
sex were always included in all analyses. For methylation data, we also included body mass index 
(BMI), and white blood cell type proportions inferred from the methylation levels of the samples 
using the houseman algorithm [178]. Sample descriptive (age and sex) are listed in Table 4.  
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Table 5. A complete list of phenotypes tested in the three studies along with their definitions.  
STUDY PHENOTYPE SAMPLE 
SIZE (N) 
MEAN (RANGE, SD) 
/ CASES (%) a 
DEFINITION 
Smoking biomarker - Nicotine metabolism and exposure 
I Nicotine metabolite 
ratio (NMR) 
1518 0.4 (0.01-2.0, 0.23) Proxy for the rate of nicotine metabolism; calculated as 
the ratio of 3-hydroxycotinine to cotinine. 
II Cotinine 310 192.7 (5.1-820.5, 
148.43) 
Reliable indicator of nicotine exposure. Serum cotinine 
levels (ng/ml) measured using mass spectrometry.  
Self-reported smoking 
III Smoking initiation 1998 1660 (83%) Smoked at least 100 cigarettes in lifetime and at least 
once a week for at least two consecutive months. 
III Cigarettes per day (CPD) 1998 18.8 (1.5-45, 10.2) Number of cigarettes smoked per day during the 
month of heaviest smoking; eight categories: 1-2, 3-5, 
6-10, 11-15, 16-19, 20-25, 26-39, and ≥40 CPD. 2 
III Maximum CPD 1998 29 (0-98, 14.3) Maximum number of cigarettes ever smoked during a 
day (24h period). 
III FTND (≥4) 1998 798 (40%) Nicotine dependent if ≥4 out of 10 points in 
Fagerström Test for Nicotine Dependence. 
III FTND score 1998 3.5 (0-10, 2.4) Fagerström Test for Nicotine Dependence score (range 
0-10). 
III DSM-IV nicotine 
dependence diagnosis 
1998 844 (42%) DSM-IV diagnosis for nicotine dependence (≥3 
symptoms out of 7 occurring within a year). 
III DSM-IV nicotine 
dependence symptom 
count 
1998 2.9 (0-7, 1.7) Number of DSM-IV nicotine dependence symptoms 
(range 0-7). 
III DSM-IV nicotine 
withdrawal diagnosis 
1998 522 (26%) DSM-IV diagnosis for nicotine withdrawal (≥4 
symptoms out of 8 occurring within a year). 
III DSM-IV nicotine 
withdrawal symptom 
count 
1998 2.3 (0-8, 2.1) Number of DSM-IV nicotine withdrawal symptoms 
(range 0-8). 
Smoking associated comorbidities 
III Regular drinker 1998 1183 (59 %) Drinks at least one alcoholic drink at least once a week 
III Heavy drinker 1998 856 (43%) Drinks at least five or more alcoholic drinks once a 
week. 
III Maximum drinks 1998 14.7 (1-72, 9.8) Maximum number of alcoholic drinks ever consumed 
in one day (24-hour period). 
III DSM-IV alcohol 
dependence diagnosis 
1998 103 (5%) DSM-IV diagnosis for alcohol dependence (≥3 
symptoms out of 7 occurring within a year). 
III DSM-IV alcohol 
dependence symptom 
count 
1998 1 (0-7, 1.6) Number of DSM-IV diagnosis for alcohol dependence 
(range 0-7). 
III Schizophrenia (SCZ) 73 18 (25%) Diagnosis of schizophrenia was assigned per DSM-IV 
criteria 
a Mean, range and standard deviation are presented for quantitative traits while number of cases and % 
are presented for binary phenotypes.  
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4.3 Omics data 
This section describes the different data layers analyzed in the three studies. All omics datasets 
were produced with microarray-based technology. Figure 3 on page 7, provides an overview of 
the workflow of the microarray. Methods for analyzing these data are described in the next 
section (4.4. Analyses). All the data was available at different stages of processing: Genotype data 
for all studies was available post-QC (described in section 4.3.1 below) and imputation for 
analysis. Methylation data used in Study I and III were available post-QC and normalization 
(detailed in section 4.3.2), whereas for study II data was processed from raw intensity files 
(detailed in section 4.3.2). Expression data for SCZ dataset were processed and analyzed at Yale 
University while expression data for study III (DILGOM) was preprocessed and normalized at 
Estonian Genome Center, University of Tartu and was made available for analysis. In the following 
sections, quality control and data processing for genotype, methylation, and gene expression 
data is described.   
4.3.1 Genotype data 
Genotype data (SNP data) used in this thesis, was produced at the Wellcome Trust Sanger 
Institute, UK and the Broad Institute of MIT and Harvard, USA. Figure 5 details the genotype data 
processing as well as standard quality control (QC) criteria applied to the genotyped and imputed 
Genotype data: 
Produced with Illumina Human 
arrays:
670-QuadCustom & CoreExome 
(FTC), 610-Quad (FINRISK, YFS)
Quality Control on genotyped SNPs :
SNPs with minor allele frequency (MAF)<1%
SNP call rate<95%
Hardy Weinberg Equilibrium (HWE) P-
value<1E-06
Imputation: 
Pre-phasing with SHAPEIT2 
Imputation with IMPUTE2 -
1000 Genomes Phase I/III 
reference panel
Post imputation quality control:
SNPs with MAF<1%
SNP call rate<95% (<99% for MAF<5% SNPs)
HWE P-value<1E-06
Imputation info score<0.4
Figure 5. Figure illustrating the process of genotype data processing including imputation to reference 
panel along with the quality control (exclusion) criteria pre-and post-imputation. 
Results & Discussion 
 
24 
 
data. QC and imputation for all genotype data were done centrally at the Institute for Molecular 
Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland. In addition to post- 
genotyping-QC thresholds (detailed in Figure 5) applied to exclude bad quality SNPs, samples 
were excluded if call rate<95%, and if they failed in heterozygosity test and sex checks, or were 
outliers in Multidimensional Scaling plots. The QC thresholds in Figure 5 apply to all the arrays 
except for CoreExome chip where minor allele frequency (MAF) cut-off of minor allele count <2 
was applied.  
In study III, we tested the association between rare variants (MAF<0.01) and smoking as 
well as alcohol-related phenotypes. Given the low frequency of rare variants (power loss) and 
owing to the burden of multiple testing [179], we only analyzed variants located in coding and 
regulatory regions (enriched with phenotype associated rare variants [180]). Low frequency 
(MAF<0.05) and rare variants (MAF<0.01) were imputed, hence post-imputation QC criteria 
(Figure 5) were not applied to the NAG-FIN sample used in Study III. As study III is focused on the 
ten key genes in the NSP (Table 2 on page 12); genotypes were extracted based on the longest 
isoform reported at the UCSC Genome browser (per GRCh37/hg19) for each gene and 50kb 
flanking region. In all genetic association studies where FTC samples were used, only one 
individual from a monozygotic twin pair was included as they have identical genotypes, whereas 
both individuals from dizygotic pairs were included in the analyses. 
4.3.2 Methylation data 
Methylation data was generated using the Illumina Infinium HumanMethylation450 
BeadChip (450k) at the Technology Centre, FIMM, Helsinki, Finland, the Microarray consortium, 
Oslo, Norway, The Genomics facility, University of Chicago, IL, USA and at the SNP&SEQ 
Technology Platform, University of Uppsala, Sweden. All samples were derived from peripheral 
blood, bisulfite converted using EZ-96 DNA Methylation-Gold Kit (Zymo Research, Irvine, CA, USA) 
according to the manufacturer’s instructions and assayed on the 450k array. Figure 6 illustrates 
the processing of methylation data for analysis. To ensure good quality of data several QC metrics 
were applied. Probes with detection P-value>0.05 were discarded as per Illumina’s 
recommendation to ensure captured signal was not background noise. Sample and probes were 
filtered out with a threshold of call rates>95%. For study II, detection P-value threshold was 
lowered to P-value≥10E-16 (such that probes on Y-chromosome were no longer detected among 
females) based on the recommendation by Lehne et al. [54]. Samples with gender mismatch 
(inferred based on the deviation from median intensities of probes mapping to X and Y 
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chromosome) were also excluded. To avoid spurious associations, probes that may be unreliable 
because of non-specific binding [181], presence of SNPs in probe body or at the CpG site [182], 
or insertions, deletions, and repetitive DNA [183] (listed as ad hoc exclusion criteria in Figure 6) 
were further excluded. Methylation data was used as beta value (percentage methylation) in all 
analyses. Calculated as the ratio of intensities between methylated versus combined locus 
intensity, and ranges between 0 (fully unmethylated) and 1 (fully methylated): 
 
Methylation data utilized in the three studies was pre-processed and normalized using the 
Bioconductor R packages ‘minfi’ [53] (study I, II and III) and ‘limma’[184] (study II) with varying 
normalization methods and QC criteria as described below for each study. For sample QC based 
on number of bead counts ‘wateRmelon’ R package [185] was used. For annotation of the probes 
on 450k array, we used R package ‘IlluminaHumanMethylation450kanno.ilmn12.hg19’ and the 
data available by Zhou et al. [186].  
 
Figure 6. Figure illustrating the methylation data pre-processing and normalization. 
In study I and III, only targeted regions were analyzed for assessing the role of methylation. In 
study I, CpG sites were chosen based on genomic coordinates mapping to the 4.2Mb (plus 500kb 
flanking) region containing the genome-wide significant loci identified in the GWAS meta-
analyses of NMR. CpG sites mapping to this region were extracted from a 450k dataset processed 
with functional normalization [55] implemented in R package ‘minfi’ with the function ‘FunNorm’ 
Methylation data:
Illumina’s Infinium 
HumanMethylation 450k 
BeadChip
Pre-processing:
Raw intensity data read
Background subtraction performed
Quality control:
Call rates<95%
Detection P-value>0.05
Ad hoc exclusion: Probes with SNPs
Cross-reactive/hybridizing probes
Normalization:
Stratified Quantile Normalization (study I)
Quantile Normalization ( study II) 
Subset Quantile within array (study III)
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that uses control probes to remove unwanted technical variation as well as diminishes batch 
effects. A total of 1424 (out of 2268) CpG sites were taken forward for analysis after excluding 
unreliable probes. As the sample size for methylation data was small (N=171), further filtering 
was performed based on interquartile range (IQR) to only keep probes showing reasonable 
interindividual variability (IQR>0.05), leaving 158 sites for the analysis. In study III, CpG sites 
mapping to the ten NSP genes were selected from a Subset-Within Array normalized [52] dataset 
(DILGOM, N=512). The normalization was performed using ‘preprocessSwan’ function in ‘minfi’ 
R package which performs quantile normalization on the data based on subsets of probe types (I 
and II) as well as adjusts for the number of CpGs in the probe body. Altogether, 254 CpG sites 
mapped to the ten NSP genes (Table 2 on page 12), and 226 of these passed the QC criteria. In 
study II, the whole epigenome captured by the 450k array was analyzed using the pipeline 
suggested by Lehne et al. [54] with one additional QC criteria i.e. bead count>3 per sample. Post 
QC, N=310 samples and 323,478 probes remained. The intensity values were quantile normalized 
using the function ‘normalizeQuantiles’ in R package ‘limma’ [184] based on six different probe-
type categories defined by color channel, probe-type and M/U subtype [54]. Normalized intensity 
values were used to calculate the methylation beta values at each CpG site which were used for 
the epigenome-wide analysis. 
4.3.3 Expression data 
Expression data from peripheral blood was produced with Illumina HT-12 expression array for 
the DILGOM sample (N=512) at Estonian Genome center, Tartu, Estonia and Illumina Human 
WG6 v3.0 Expression BeadChip for the SCZ sample (N=71) at University of California Los Angeles, 
USA. Expression datasets were used in study III for eQTL analysis and differential expression 
analysis of the ten NSP genes (Table 2 on page 12). Expression arrays were preprocessed with 
Illumina’s BeadStudio software, followed by quantile normalization using R package ‘Affy’ [187]. 
Technical replicates were averaged to obtain one value per sample and log-transformed values 
were used for the analysis [166]. Probes were mapped to gene names using R package 
‘illuminaHumanv4.db'. Altogether, 19 probes mapped to the ten NSP genes, but only 17 passed 
QC criteria (probes mapping to non-autosomal chromosome, erythrocyte globin components or 
multiple genomic loci were removed) resulting in the exclusion of two probes mapping to PSENEN 
gene. One probe per gene was selected if it had the highest IQR for that gene to only test 
association with probes with most biological variation. Data from the SCZ sample was otherwise 
identically processed, except that rank normalization was applied and low signal strength probes 
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were excluded [188]. The same probes as selected in the DILGOM sample were picked from the 
SCZ sample. 
4.4 Analyses 
Analyses performed in the three studies are covered in this section. As summarized in Figure 1, 
the hypothesis-free approach was applied in study I and II, to examine the association of genome-
wide genetic and epigenetic variants with NMR and serum cotinine levels, respectively. For study 
III, a hypothesis-driven, targeted approach was applied to extensively scrutinize association 
between genetic variants in the ten NSP genes (Table 2 on page 12) and a wide-range of smoking 
and alcohol use phenotypes (Table 5 on page 22). Integrative omics analyses to assess the 
potential function of variants associated with the phenotypes are also described in this section. 
Except for study I (GWAS-meta analysis of NMR), where a standard genome-wide significance 
threshold (P-value<5E-08) [189] was applied, statistical significance was declared when false 
discovery rate (FDR)[190] adjusted P-value<0.05, unless stated otherwise.  
4.4.1 Association analysis (Study I, II & III) 
With the aim to scrutinize the association of genetic and epigenetic variants with smoking 
behavior phenotypes we employed the following statistical methods:  
4.4.1.1 Association of genetic variants 
Association of common and low-frequency variants (Study I and III) 
To assess the association of genetic variants (SNPs) with the quantitative traits, we employed 
univariate linear mixed model implemented in GEMMA (genome-wide efficient mixed-model 
association)[191] with the phenotype as the dependent variable and genotype along with 
covariates age and sex as fixed effects of the model.  
Population stratification and genetic correlation (relatedness) in the sample was modeled with 
additional random effects using a covariance matrix estimated from the correlation (relatedness) 
of genome-wide genotype data across samples as implemented in GEMMA [191]. Only common 
(MAF>0.05) and low-frequency variants (0.05≥MAF≥0.01) were analyzed with GEMMA, and tests 
for rare variants (MAF<0.01) are described below. 
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Association of rare genetic variants (Study III) 
In study III, we analyzed the rare variants (MAF<0.01) residing in coding regions, splice sites, 
promoters and untranslated regions of the ten NSP genes (Table 2 on page 12) with the aim to 
identify additional genetic contribution to the variation observed in the phenotypes tested. We 
performed single-variant and gene-based tests (as single-variant tests suffer from statistical 
power loss [192]). In single variant association analysis, we used ‘lmekin’ function implemented 
in R package ‘coxme’ [193] for quantitative traits and ‘pedigreemm’ [194] for binary traits to 
assess the association between phenotype and SNP with linear mixed effects model. To account 
for the relatedness in our sample a kinship matrix was included in random effects, while age and 
sex were added as covariates (fixed effects). Gene-based tests were performed using R packages 
‘SKAT’ (SNPset (Sequence) Kernel Association Test) [195] for quantitative traits and ‘HBMR’ 
(Hierarchical Bayesian Multiple Regression model) [196] for binary traits. SKAT performs multiple 
regression to compute P-values based on the variance component of the aggregated set of SNPs 
in a region. HBMR performs multiple regression utilizing information on the relative contribution 
of variants toward the variance observed in the phenotype while also accounting for the 
genotyping quality. HBMR reports Bayes factors (BFs), and we considered nominal significance 
when BF>2.45, corresponding to a P-value<0.05 [197, 198].  
Meta-analysis (Study I) 
We performed a meta-analysis to combine the results from the three Finnish cohorts using META 
software employing the fixed effects model [99]. We used the ‘inverse variance’ method, wherein 
the effect size was estimated as the sum of beta estimates from each cohort weighted by the 
inverse of their sample variance and genomic control inflation factor.  
Conditional analysis (Study I) 
We performed conditional analyses to ascertain independent loci in the regions genome-wide 
significant signal in the GWAS meta-analyses of NMR. SNP with the lowest p-value in the meta-
analysis was assumed to be the first independent loci. The genotype for this top SNP was then 
added as a covariate to the regression model in the separate cohorts and then meta-analyzed. 
SNP with the lowest P-value identified in this round was declared as the second independent 
signal. The top two SNPs were then together added to the regression model to further identify 
significant hits. This process was repeated until no further genome-wide significant association 
was observed. 
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Percentage of variance explained (Study I & II) 
To estimate the proportion of variance explained by individual SNPs, we calculated the difference 
of R2 between the two models i) Phenotype regressed only on the covariates (age, sex, BMI) and 
ii) model including the SNP along with the covariates. 
Genetic Risk Score (Study I and II) 
We calculated a genetic risk score (GRS) using the independent top SNPs from the meta-analysis 
in study I (rs56113850, rs113288603, esv2663194, and rs12461964; Table 7). The GRS was 
calculated as a weighted (by their estimated effect sizes) average of the major allele counts. The 
GRS was used to predict smoking behavior in two non-overlapping Finnish cohorts using logistic 
regression (to model current daily versus former smoking) and hurdle regression (to model 
smoking quantity among current smokers). In study II, we used this GRS to account for the effects 
of NMR on cotinine levels. For the sample included in study III, esv2663194 was not available, 
thus the GRS was constructed using only three SNPs (rs56113850, rs113288603, and 
rs12461964).  
Joint linkage and LD analysis of common variants (Study III) 
Linkage analysis and allelic association (also referred to as LD) when combined (joint linkage and 
LD) can be more informative in genome mapping. To utilize the extended family structure in our 
discovery sample (NAG-FIN) for study III, we scrutinized the genetic variants for linkage as well 
as joint linkage and LD with the PSEUDOMARKER software [199, 200] which implements the 
Elston–Stewart algorithm for full-likelihood. Only binary phenotypes and common variants 
(MAF≥0.05) were analyzed with PSEUDOMARKER assuming a recessive mode of inheritance. 
4.4.1.2 Association of epigenetic variants (Study II) 
To assess the association between methylation and serum cotinine levels, we performed 
epigenome-wide association analysis using pipeline suggested by Lehne et al. [54]. Modifications 
were made to the pipeline to accommodate the relatedness of our sample as explained below. 
In accordance with the pipeline, 30 principal components (PCs) based on the control probe 
intensities were used as covariates in the model to account for technical variance in the data. 
Intermediate residuals were estimated by regressing these 30 control probe PCs, age, sex and 
BMI on the methylation beta values. For any unaccounted global biological covariance, 10 PCs 
from based on the intermediate residuals were also included in the regression model. Houseman 
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algorithm [178] was employed to infer the white cell type distributions to be included in the 
regression model as well.  
We employed linear mixed effect model using function ‘lmer’ in the R package ‘lme4’ [201] with 
methylation at each CpG as the dependent variable and serum cotinine level along with age, sex, 
BMI, white blood cell types and batch variable (for cotinine measurements performed at two 
different facilities; section 4.2) as covariates in the fixed effects part of the model. To account for 
relatedness in the sample, family and zygosity were included as additional random effects.  
Secondary EWAS: Cotinine levels are affected by the amount of nicotine intake as well as the rate 
of nicotine clearance. To account for the influence of NMR on cotinine levels we utilized the NMR 
GRS (described above; Study I) as an additional covariate in the model. 
Visualization of results (study I, II and III) 
For Manhattan and QQ plots, R package ‘qqman’ [202] was utilized. LD structure of the SNPs 
highlighted in the analysis was visualized using Haploview software[203]. LocusTrack [204] was 
used to create regional plots for top associations. Circos plot depicting meQTLs were created 
using the R package ‘Rcircos’ [205]. 
4.4.2 Differential expression and methylation analysis (Study III) 
As our association and joint linkage and LD analysis, revealed association between variants NSP 
genes and smoking behavior, we examined whether gene expression and methylation levels in 
these genes differ between smokers and non-smokers. Differential expression and methylation 
analysis were performed using linear regression (‘lm’ function in R) while adjusting for age, sex, 
and BMI. We further adjusted for estimated white blood cell proportions while comparing 
methylation levels. Owing to the high comorbidity between smoking and SCZ [80], we also 
examined the confounding effect of smoking on differential expression of the NSP genes in SCZ. 
We examined differential expression between SCZ cases and controls, adding age and sex as 
covariates while adjusting for relatedness in the sample with a kinship matrix. We then added 
smoking status (defined as smoker versus non-smoker) as a covariate to detect any confounding 
effects.  
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4.4.3 Quantitative Trait Loci analysis (Study I, II & III) 
To assess the effect of SNPs associated located in the non-coding region of the genome, we 
performed methylation (meQTL) and expression quantitative trait loci (eQTL) analyses. In study 
I, we examined the association between SNPs and methylation levels of the CpG sites in the 
region with the genome-wide significant signal, by regressing methylation beta values against the 
genotype count of the coded allele (0, 1, or 2), while accounting for age and sex. In study II & III, 
we utilized the R package ‘MatrixEQTL’ [206] with the linear model setting to examine the 
association of the highlighted SNPs with methylation levels (meQTLs). Age, sex, BMI, smoking 
status (cotinine levels in study II) and white blood cell subtypes were included as covariates. In 
study II, we also included a covariance matrix based on the methylation levels of the top CpGs to 
account for relatedness in our sample. As opposed to study I and III, where the regions analyzed 
were targeted and we considered only cis interactions, in study II we also tested trans 
interactions. A cis distance of 2.5Mb (longest gene was ~2.4 Mb) was chosen to accommodate all 
possible combinations of SNP-CpG pairs for a given gene, while all other interactions were 
considered trans. In study III, we also assessed the association of top SNPs with expression levels 
of the NSP genes (eQTLs). We used identical procedure as for meQTLs except that white blood 
cell counts were not included in the model (to have comparable results for replication in publicly 
available datasets/resources).   
4.4.4 Mediation analysis (Study I & II) 
To investigate if methylation is a mediator between the observed association of genotype and 
phenotype, we performed causal inference test (CIT) [34] (Figure 7). CIT was conducted only for 
candidate SNPs that met the two basic conditions of association with the phenotype (NMR or 
cotinine levels) as well as methylation, the potential mediator. As illustrated in Figure 7, we 
examined the mediation by methylation between the observed association of SNPs with NMR 
(study I) and cotinine levels (study II).  
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Figure 7. Illustration of mediation analysis setup performed using causal inference test (CIT), a 
mathematical framework used to assess mediation. CIT tests conditional association for genotype (G), 
potential mediator (M, methylation), and phenotype (P): (i) G is associated with P, (ii) G is associated with 
M, (iii) P is associated with M conditional on G and (iv) P is independent of G conditional on M.  
4.4.5 Annotation of association findings (Study I, II and III) 
In addition to employing in-house data, we also utilized several tools and databases (summarized 
in Table 6) for inferring predicted functional potential, pathway analysis, replication of our 
findings, and assessing tissue specificity of our results. All listed resources, except IPA, are public 
and freely available. 
Table 6. Tools and databases utilized in performing annotation of highlighted associations. 
Study Resource  Description Weblink 
I, 
III 
Variant effect 
predictor (VEP) 
Provides information on the potential effect of the variants within 
genes as well as regulatory regions [207] 
www.ensembl.org/Tools
/VEP  
II Ingenuity pathway 
analysis (IPA) 
Provides information on the enrichment of metabolic and signaling 
pathways in the data. [208] 
www.qiagenbioinformat
ics.com/products/ingen
uity-pathway-analysis/  
III GTEx Contains genotype and expression profiles across 53 different 
tissues (as of September 2017) enabling eQTL studies across 
tissues [209] 
www.gtexportal.org  
 BRAINEAC Brain eQTL Almanac provides genotype and expression profile 
across 10 brain regions [210] 
http://braineac.org/  
 mQTLdb Database with methylation and genotype data on mother-child 
pairs providing access to meQTL mapping across five different 
stages of life in two tissues (peripheral and cord blood) [211] 
www.mqtldb.org/  
 Fetal brain meQTLs Epigenome-wide significant meQTLs observed in fetal brain [212] http://epigenetics.essex
.ac.uk/mQTL/  
 Schizophrenia 
Genetic Research 
database (SZDB) 
Collective database for SCZ research containing genetic, gene 
expression, network-based data from several studies. [213] 
www.szdb.org  
 HaploReg v4 Provides regulatory potential of non-coding SNPs [214] www.encodeproject.org
/software/haploreg/  
 SPANR Splicing disruption potential of coding and non-coding variants [215] http://tools.genes.toron
to.edu/  
 450k Annotation Comprehensive annotation data for 450k array [186] http://zwdzwd.github.io
/InfiniumAnnotation  
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5 Results & Discussion 
 
5.1 Study I: Genetic variants associated with nicotine metabolism rate and their 
interplay with methylation  
GWAS using metabolites measured from serum such as glucose, insulin, and lipids have 
been highly successful in identifying underlying genetic risk factors [72, 73] and therefore 
represent powerful intermediate phenotypes for complex traits. To identify novel genetic 
variants associated with nicotine metabolism rate, using a ratio of nicotine metabolites 3-
hydroxycotinine and cotinine (NMR), we performed a GWAS meta-analysis with three Finnish 
cohorts (N=1518). We observed a strong association signal at 19q3.2 locus. A total of 719 SNPs 
reached genome-wide significance (P-value<5E-08) within a 4.2 Mb region (hg19 build 
coordinates 19:39546965–43710562). Manhattan plot for the NMR GWAS meta-analysis is 
presented in Figure 8. 
Figure 8. Manhattan plot for the NMR GWAS meta-analysis with zoomed in region on 19q3.2. Figure 
modified from Loukola et al. PloS Genet 2015. 
A SNP in the intron 4 of CYP2A6, rs56113850 (referred to as index SNP here on), was the 
top association in the meta-analysis (P-value=5.77E-86). Conditional analysis of this region 
revealed three independent SNPs (Table 7), with rs12461964 appearing as a fourth independent 
signal only in the FINRISK2007 sample. Rs113288603 (not genome-wide significant in GWAS 
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meta-analysis) emerged as an independent signal only when the conditional analysis was 
performed on the index SNP. An interplay between the index SNP (rs56113850) and rs113288603 
was observed, such that adding the index SNP to the model changed the association from non-
significant (Beta=0.05, P-value=0.522) to genome-wide significant (Beta=-0.47, P-value=1.32E-
09). The index SNP also showed an increase in the magnitude of effect size from -0.65 to -0.82 
(P-value<2E-16) when rs113288603 was added to the model. Adding an interaction term 
between rs113288603 and the index SNP further increased the magnitude of effect size for 
rs113288603 (Beta=-0.62, P-value=1.32E-03) but not for the index SNP (Beta=-0.82, P-value <2E-
16). These results indicate that the index SNP and rs113288603 act in concert and their interplay 
should be examined in future studies. 
Table 7. Independent signals identified with conditional analysis. 
SNP Position Reference 
allele 
Minor 
allele 
MAF c Beta (minor 
allele) 
P-value d 
rs56113850 chr19:41353107 T T 0.44 -0.65 5.77E-86 
rs113288603 a chr19:41362293 C T 0.15 -0.02 7.03E-25 
esv2663194 chr19:41355733 G <DEL> 0.03 -1.08 8.49E-20 
rs12461964 b chr19:41341229 A A 0.45 -0.61 3.66E-16 
a No association in the GWAS meta-analysis, but appeared as an independent signal in analyses conditioned on 
the index-SNP 
b Emerged as an independent SNP only in the FINRISK2007 sample 
c Minor Allele Frequency (MAF) calculated from a large FINRISK sample (N=19,857)  
d P-values from each meta-analysis conditioned progressively in the order of SNPs listed in the table.  
 
All the independent SNPs were in or near (≤8kb) CYP2A6, the main nicotine metabolizing 
enzyme. Minor alleles for all top variants had a decreasing effect on NMR corresponding to a 
decrease in nicotine clearance rate (Table 7). The index SNP (rs56113850) by itself, explains a 
fairly large proportion of variance in NMR ranging between 14-25% in the three cohorts included 
in the study and has a prominent effect size (Beta=-0.65). Similarly, the indel esv2663194 has a 
large effect size (Beta=-1.08). Together the three independent SNPs (rs56113850, rs113288603, 
and esv2663194) explain 20.8% variance in FinnTwin, 31.4% in YFS, and 26.3% in FINRISK2007 
cohorts. In FINRISK2007, including the fourth independent SNP rs12461964 increased the 
variance explained to 27.7%.  
We constructed a weighted genetic risk score (GRS) based on the independent SNPs and 
tested if it could predict smoking behavior in the NAG-FIN and non-overlapping FINRISK samples. 
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The GRS was calculated using the major allele counts and corresponding effect sizes, such that 
higher GRS parallels faster nicotine metabolism. First, we tested if the GRS associates with 
cigarettes per day (N = 3954) and second with smoking status i.e. current smokers (N= 3954) 
versus former smokers (abstinence of ≥ 6 months; N= 3543). Results were comparable for the 
GRS with three and four SNPs. The GRS was positively associated with cigarettes per day in 
current smokers (Beta=0.10, P-value=0.002), indicating that individuals with faster metabolism 
smoke more, in line with earlier evidence [216]. The GRS was also associated with increased 
likelihood of being a former smoker (OR=1.39, 95% CI 1.09 1.76, P-value=0.007). However, in 
the sensitivity analysis, when effects of potential confounders for smoking cessation (adverse 
health effects/diagnosis of major depressive disorder, cancer, or cardiovascular diseases) were 
taken into consideration, and the model was adjusted for alcohol consumption, the association 
became non-significant (OR=1.30, 95% CI 0.95-1.78, P-value=0.10). This may be due to lack of 
statistical power or GRS not capturing certain relevant aspects of smoking cessation success, 
preventing us from replicating previous findings that show slow metabolizers quit more often 
than normal metabolizers [105, 217]. However, the GRS still captures a considerable proportion 
(~30%) of the variance in NMR and can be of great utility in clinical settings to personalize 
cessation therapeutics based on genetically determined nicotine metabolism profiles [218]. 
For annotation of the probable role of the genome-wide significant SNPs, we considered 
the following hypotheses (results summarized in Figure 9): SNPs directly affect the function of 
the CYP2A6 enzyme or are in LD with known functional variants of CYP2A6, or epigenetic 
mechanisms like methylation regulate the gene function. According to variant effect predictor 
(VEP; Table 6), the four independent SNPs did not have any predicted functional effects. Except 
for rs113288603, the other three independent SNPs shared LD blocks with the known functional 
variants of CYP2A6 (https://www.pharmvar.org/htdocs/archive/cyp2a6.htm)[106]. To assess the 
role of epigenetics (methylation), we performed meQTL analysis and identified 173 SNPs 
associated with methylation levels at 16 CpG sites in the region harboring genome-wide 
significant association signal. We further performed CIT to examine whether methylation at any 
of these sites mediates the effect of genotype on NMR. We observed that methylation at the CpG 
site cg08551532 (in DLL3 gene) mediates the effect of SNPs on NMR. Our meQTL and CIT results 
indicate that epigenetic mechanisms such as methylation may play a role in regulating at least 
some of the genes identified in this GWAS. It must be noted that the most interesting gene, in 
this case, CYP2A6 could not be tested for meQTLs as none of the CpG probes mapping to it passed 
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QC. Targeted exploration of methylation in CYP2A6, for example using Epityper or bisulfite 
sequencing, would be required for further investigation of this region. 
Figure 9. Summary of annotation results for the genome-wide significant SNPs identified in GWAS meta-
analysis. 
Although we examined epigenetic mechanisms potentially involved in mediating the 
effects of NMR associated SNPs, further investigation of these loci with extensive functional 
assessments would be valuable. For instance, other forms of genetic (rare variants, copy number 
variants, etc.) and epigenetic (histone modifications) variations, that were not captured in our 
study are essential. Sequencing of the highlighted locus for genetic and epigenetic variants could 
provide a better resolution into this region of the genome and identify additional factors 
contributing toward the variance in nicotine clearance rate and its consequent effects on smoking 
behavior and associated disease risk. 
This study was performed in Finnish population samples, and the results may be specific 
to Finnish population. Replication of our findings in other populations is of importance. Two 
recent studies in European, African, and Asian American individuals by Baurley et al. [108] and in 
African Americans by Chenoweth et al. [109] also performed GWAS meta-analysis of NMR. 
Baurley et al. [108] replicated our top association, however, less than 40% overlap was observed 
with Chenoweth et al. [109] findings. Only one of the three independent SNPs in the African 
American study [109], rs12459249 was genome-wide significant in our meta-analysis (P- 
value=3.28E-76). These results provide support to our findings as well as highlight the population 
specificity of nicotine metabolism [103]. Observed differences may also be due to different 
genotyping platforms and imputation panels used in the three studies, and to a smaller extent 
because of hormonal (estrogen-induced CYP2A6 activity) and demographic factors such as age, 
sex, BMI, alcohol, and cigarette consumption [219].  
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Our study was the first GWAS on NMR, where we identified robust associations at 19q3.2 
locus encompassing the main nicotine metabolizing enzyme CYP2A6 including several novel 
associations. Our study also demonstrates the value of a biomarker as a phenotype in a GWAS 
meta-analysis with modest sample sizes. Our findings of novel genetic variants associated with 
NMR and the possible role of epigenetic variation in the highlighted locus hold great value for 
aiding personalization of cessation therapeutics (as discussed in chapter 6). 
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5.2 Study II: DNA methylation associated with serum cotinine levels of regular 
smokers 
As demonstrated by numerous EWAS (Table 3 on page 13), smoking has been extensively 
associated with DNA methylation levels. Self-reported smoking status and quantity have been 
widely utilized in such EWAS, identifying genes such as AHRR, ALPPL2, and F2RL3 consistently. 
However, self-reported smoking status and quantity are prone to error due to misreporting and 
recall bias [66, 220]. Cotinine, on the other hand, is a reliable indicator of nicotine exposure [66]. 
Thus, we utilized serum cotinine levels as a continuous phenotype in an EWAS, performed in a 
sample of biochemically verified regular smokers (serum cotinine>4.85ng/ml), allowing us to 
assess the direct effects of nicotine exposure on methylation. We further evaluated the role of 
genetic variants in the genes identified in the EWAS and assessed whether methylation at the 
identified loci is a cause or consequence of nicotine exposure. Figure 10 summarizes the study 
design and the main findings. 
In our EWAS of regular smokers, we identified methylation at 50 CpG sites (in or near 35 
genes) significantly associated with cotinine levels. Among the 50 CpG sites, 33 CpG sites have 
previously been reported while 17 are novel (never reported as genome-wide significant in 
previous studies; Table 3 on page 13). Nine of the previously reported CpG sites were identified 
only in studies using self-reported smoking status with much larger samples (~1000 or more) 
[135, 141, 142], in contrast to our sample of 310 individuals, showing the power afforded by 
biomarker (a reliable and informative phenotype). An extended table of results from the EWAS 
is in Appendix I.  
The top association was observed at cg05575921 in AHRR gene (P-value=3.3E-18), the 
most consistently reported association (Table 3). In line with earlier reports, we also observed 
CpG sites in ALPPL2 (minimum P-value= 1.9E-15 for cg05951221) and cg03636183 in F2RL3 (P-
value= 1.9E-11) [133, 139, 141, 221]. Also, consistent with previous studies, for a substantial 
portion of the highlighted CpG sites (42 out of 50), methylation levels were negatively associated 
with cotinine levels; parallel to lower methylation with smoking exposure in other studies. A key 
observation is that the novel associations identified in our EWAS were in smoking-related genes 
such as cg13740236 in LSM6 (P-value= 2.9E-08), cg05992400 in CYP2C18 (P-value=4.9E-06), and 
cg26589665 in THSD4 (P-value= 3.8E-07) covered in the following sections.  
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As cotinine level is influenced by both nicotine intake as well as nicotine clearance rate, 
we added a three SNP GRS, based on the findings from study I, to account for nicotine metabolism 
rate to the model. In this secondary EWAS, methylation at a total of 30 CpG sites (in or near 20 
genes) was significantly associated with cotinine levels, five of which were novel (never reported 
as genome-wide significant in previous studies; Table 3 on page 13) and 25 overlapped with the 
discovery EWAS results. Interestingly, when the GRS was added, half of the associations from the 
discovery EWAS were no longer genome-wide significant (FDR P-value>0.05) in the secondary 
EWAS. This suggests that these genes are likely influenced by or are involved in nicotine 
metabolism. Pathway analysis of these genes (genes no longer genome-wide significant in the 
secondary EWAS), were enriched in xenobiotic and nicotine degradation metabolic pathways. 
The two genes mainly involved in these pathways are CYP2C18 and AHRR, both related to the 
cytochrome P450 (CYP) family - a major source of variability in drug pharmacokinetics and 
response [222]. AHRR is a regulator of CYP genes. This show that the GRS accounts for the effect 
of nicotine metabolism on cotinine levels. However, the GRS based only on three SNPs does not 
capture the entire effect of NMR as a high proportion (~70%) of the variance in NMR remains 
unaccounted. A GRS composed of more SNPs (explaining more variance) or a more composite 
measure that could incorporate contribution of other mechanisms (such as epigenetics) that 
explain variance in NMR, would be ideal to account for the influence of nicotine metabolism rate 
more comprehensively.  
A total of 55 unique CpG sites (in or near 40 genes) were identified in the EWAS (discovery 
and secondary) that were associated with cotinine levels. We observed that some of the 
highlighted genes in our EWAS harbor genetic variants previously reported for association with 
smoking-related phenotypes, for example, SNPs in THSD4, LSM6, and CNTNAP2 are associated 
with nicotine dependence [223], and LSM6 and CACNA2D4 with pack years (an indicator lifelong 
accumulated smoking exposure) [224]. THSD4 variants are also associated with smoking 
cessation success [225] as well as lung function affected by smoking [226]. Hence, we further 
explored the role of genetic variants in the highlighted genes. In our data, SNPs in CNTNAP2 and 
THSD4 genes were significantly associated with cotinine levels, in line with these previous 
findings. Altogether, 20 SNPs in nine genes were associated with cotinine levels, and strongest 
association was observed for rs187669467 in ARHGAP44 (P-value=3.9E-06).  
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 In the 40 genes that were identified in our EWAS, we also examined the association of 
genetic variants with methylation levels of the top 55 CpG sites and identified 124 cis and 3898 
trans meQTLs demonstrating both proximal and distal interaction between nicotine exposure 
associated methylation and SNPs. Interestingly, among the 20 SNPs that were associated with 
cotinine levels, 19 were also meQTLs. We performed CIT to investigate the role of DNA 
methylation as a mediator between the association of genotype and cotinine levels at these loci. 
We observed a trend (P-value<0.05) of mediation at 7 CpG sites with SNPs in distal genes, 
suggesting that methylation at these loci may not be a consequence of nicotine exposure but 
rather a causal mediator in the pathway between genotype and cotinine levels. These findings 
are crucial and require experimental validation.   
We replicated several prior associations reported between smoking and methylation, the 
novel associations identified in our study point to exposure relevant loci, but require replication 
in other population samples. This study was conducted in a sample of regular smokers in contrast 
to earlier EWAS, including the two EWAS performed using cotinine [129, 140], that included both 
smokers and non-smokers. This major difference may be reflected in our novel findings, meaning 
that our novel findings might be specific to persistent/heavy smoking. A note of caution, as 
cotinine reflects recent nicotine intake (half-life 15-20 hours), cotinine values are similar (~zero) 
for never, former and occasional smokers while their methylation profiles may not be identical 
(as noted by several EWAS, listed in Table 3). Therefore, including individuals with cotinine levels 
~zero should be avoided for methylation studies. Other sources of nicotine including snus, e-
cigarettes, and nicotine replacement therapy may also contribute to cotinine levels making the 
results not entirely specific to tobacco smoking. However, the chances of such alternative sources 
of nicotine in our sample are low, since, at the time of sample collection, the use of such sources 
was rare in Finland. Other potential sources of discrepancies in the EWAS results may be 
attributable to the difference in sample size, population specificity of methylation levels [131], 
the precision of cotinine measurement technique (higher precision with mass spectrometry 
versus immunoassay) [227], or difference in methylation data preprocessing. Further, our modest 
sample size and use of 4.85 ng/ml threshold to define current smokers (in contrast to more 
commonly used 10ng/ml, like in study I) may have introduced some noise in the association 
results, however, since several of our novel associations point to smoking-related genes the 
likelihood is small. To further verify this, we performed sensitivity analysis using a sample of 
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smokers with cotinine>10ng/ml (N=293) and observed negligible differences in the beta 
estimates for all highlighted CpG sites (Appendix I). 
In conclusion, our results showcase the power of a reliable and informative phenotype 
(biomarker) in identifying direct effects of nicotine exposure (smoking) on methylation levels. We 
replicated several earlier findings as well as identified novel biologically relevant loci, which could 
be potential targets for smoking cessation therapies. We also show that many of the identified 
methylation loci may be driven by underlying genetic variants and that methylation may be on 
the causal pathway for such smoking associated genetic variants rather than a consequence of 
nicotine exposure.   
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5.3 Study III: Smoking behavior associated functional variants in neuregulin 
signaling pathway 
The NSP, involved in neuronal migration and differentiation, has been implicated in 
smoking behavior phenotypes (SI, ND, and NW) in both a behavioral mouse model and human 
studies [114-116] (detailed in section 2.5.1). We hypothesized that several risk variants in the ten 
key functional components of the NSP (Figure 4, Table 2) might be involved in smoking behavior. 
Given the high comorbidity between smoking and other addictions, for example, alcohol [77], we 
also examined if NSP is specifically involved in smoking and not co-occurring addictions. We 
tested association, linkage, and joint linkage & LD between common (MAF>0.05), low frequency 
(0.01≤MAF≤0.05) and rare (MAF<0.01) genetic variants in the 10 NSP genes (Table 2) with a wide 
range of smoking and alcohol use phenotypes (nine smoking-related phenotypes and five 
alcohol-related; Table 5 on page 22) in the NAG-FIN sample. Alcohol-related phenotypes were 
analyzed to assess the specificity of NSP toward smoking, wherein alcohol-use phenotypes were 
representative of other addictions. Altogether 66 SNPs in seven of the ten NSP genes residing in 
23 distinct LD blocks showed significant association with three distinct phases of smoking 
behavior i.e. smoking initiation, nicotine dependence, and withdrawal. A summary of the 
associations identified and their functional annotation is provided in Figure 11. There was no 
association observed with any of the alcohol-related phenotypes, suggesting NSP’s involvement 
in smoking behavior, ruling out any confounding effects of alcohol use. Testing other addictions 
would have been ideal to further support our hypothesis (NSP’s involvement specifically in 
smoking), our study sample had limited use of other addictive substances like cannabis [228].  
We observed that most of the association signal was confined to common variants and 
the SI phenotype, which is not surprising given that ~80% of our sample had initiated smoking 
providing higher power in comparison to fewer cases of ND (42%) and NW (26%) (Table 5). Only 
one SNP, rs13385826 in ERBB4 was associated with ND (P-value=1.7E-07) in these analyses. 
Common and low-frequency variants in NRG3 and ERBB4 showed association with NW symptom 
count with large effect sizes (Beta range: -0.5 to -0.8). In single rare variant association analysis, 
no significant association was observed likely due to lack of power [179]. Gene-based rare variant 
association analysis indicated association between SI and variants in NRG1 and PSEN1, and NW 
with variants in ERBB4, demonstrating the cumulative contribution of rare variants in these 
genes.  
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Figure 11. Modified figure from Gupta et al. Transl Psychiatry 2017 showing the functional annotation of 
the 66 variants associated with smoking initiation, nicotine dependence, and nicotine withdrawal. 
Gene SNP Chr
LD 
block 
*
Effect 
allele
MAF
P-value 
**
rs183423866 1 G 0.064 1.8E-09
rs187135585 1 G 0.131 6.0E-06
PSEN2 rs10916053 1 2 A 0.396 2.1E-04
rs1836721 2 A 0.068 1.9E-05 SNP associated with SI
rs13385826 2 A 0.128 8.0E-27 SNPs associated with ND
rs184443533 2 4 T 0.117 3.2E-09 SNPs associated with NW
rs6729616 2 A 0.057 4.9E-05 * LD blocks 
rs187745320 2 A 0.137 4.5E-07 ** Lowest p-value for the SNP
rs13413099 2 A 0.216 4.0E-27 rs13385826 p-value for ND 1.7E-07
rs71350752 2 T 0.304 1.3E-07 eQTL in blood (DILGOM)
rs192584214 2 T 0.065 2.4E-07 eQTL in blood (GTEx)
rs112465988 2 T 0.052 1.3E-05 eQTL in brain (GTEx, BRAINEAC)
rs185444317 2 T 0.081 1.0E-06 meQTL in blood (DILGOM)
rs10167304 2 T 0.052 1.9E-04 meQTL in blood (mQTLdb)
rs12694263 2 C 0.050 2.1E-04 meQTL in fetal brain (Hannon et al. 2016)
rs1581385 2 A 0.364 6.7E-09 Regulatory region SNP (VEP)
rs187445356 2 8 T 0.053 6.1E-13 Missense SNP (VEP)
rs4993337 2 A 0.314 2.2E-07 Splicing disruptive (SPANR)
rs141486719 2 T 0.182 1.1E-04 Promoter overlap (HaploReg)
rs78391944 2 T 0.028 1.8E-05 Enhancer overlap (HaploReg)
rs71422776 2 A 0.035 3.5E-05
rs12990946 2 G 0.035 2.9E-05
rs35225704 2 C 0.033 9.7E-06
rs73989053 2 G 0.148 2.7E-06
rs13006797 2 G 0.136 2.1E-06
rs17328083 2 T 0.148 2.7E-06
rs13001305 2 T 0.126 2.2E-06
rs75489550 2 G 0.094 1.6E-05
rs36001505 2 C 0.061 1.9E-05
rs147786642 2 G 0.059 1.0E-05
rs113317778 8 12 G 0.096 1.3E-04
rs4327825 8 A 0.325 9.6E-10
rs4329235 8 C 0.284 9.3E-13
rs4436087 8 G 0.145 1.4E-04
rs10954844 8 A 0.152 1.7E-04
rs77085193 8 C 0.152 2.3E-04
rs17643260 8 T 0.152 2.3E-04
rs7000656 8 T 0.152 2.4E-04
rs17716671 8 A 0.152 2.4E-04
rs11780575 8 G 0.152 2.4E-04
rs17644185 8 A 0.152 2.4E-04
rs17716920 8 A 0.152 2.4E-04
rs10808325 8 T 0.152 2.4E-04
rs75974189 8 C 0.152 2.4E-04
rs11779465 8 G 0.145 2.2E-04
rs58182668 8 C 0.145 2.2E-04
rs11787140 8 C 0.152 1.9E-04
rs4733344 8 G 0.152 1.9E-04
rs12545304 8 A 0.152 2.4E-04
rs11777461 8 C 0.151 2.2E-04
rs75673683 8 G 0.152 2.4E-04
rs4733346 8 C 0.152 2.4E-04
rs7840005 8 T 0.153 2.7E-04
rs77752517 8 C 0.148 1.6E-04
rs79886978 10 T 0.081 9.8E-05
rs12774918 10 T 0.054 3.6E-07
rs11528179 10 16 A 0.074 2.9E-07
rs191742951 10 17 A 0.151 1.5E-05
rs11192578 10 18 A 0.038 1.2E-06
rs34434628 10 C 0.104 6.0E-06
rs60197472 10 T 0.390 5.6E-05
rs59013794 10 G 0.103 6.0E-06
rs7908968 10 G 0.166 2.9E-05
rs1261780 11 21 T 0.149 6.8E-05
rs191109295 11 22 G 0.191 4.0E-06
PSENEN rs807483 19 23 T 0.354 1.7E-04
Functional annotation
BACE1
NRG1
13
14
NRG3 15
19
20
APH1A 1
ERBB4 3
5
6
7
9
10
11
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Our results indicate that ERBB4 gene is associated with different measures of smoking 
behavior (smoking initiation, nicotine dependence, and withdrawal), in line with previous 
findings [114, 115], as well as provide empirical evidence for further investigation of ERBB4’s role 
in nicotine addiction. Our results also show the involvement of NRG3 in nicotine withdrawal 
symptoms; supporting the findings from a behavioral mouse model study [116] that also reported 
variants in NRG3 were associated with successful smoking cessation in humans [116].  
Except for a missense variant, rs113317778 in NRG1, all other variants identified in this 
study were in the non-coding region of the genome having unclear function or consequence. We 
performed comprehensive functional annotation of the 66 highlighted variants using epigenetic 
and transcriptomic data from an independent Finnish population sample (DILGOM), as well as 
publicly available data resources (Table 6). As evident from the visual representation of the 
results in Figure 11, we observed functional potential in a large proportion (56/60) of the 
highlighted SNPs. We utilized publicly available annotation tools (VEP and Haploreg) which 
indicated that four of the highlighted SNPs were in regulatory regions and a substantial fraction 
(24/56) overlapped enhancer and promoter sites in brain tissue. One SNP, rs13385826 in ERBB4 
which was associated with both SI and ND, was predicted to be a splicing disruption variant. Using 
in-house blood-derived data (DILGOM), we identified several SNPs that were eQTLs and meQTLs, 
many of which we could replicate in GTEx and mQTLdb respectively. Since smoking behavior is a 
neuropsychiatric phenotype, we extended this search to brain tissues availing data from 
resources like GTEx and BRAINEAC for eQTLs, and meQTLs in fetal brain [212]. We could replicate 
the majority of our meQTL findings from blood in brain tissue but not all eQTLs, suggesting that 
smoking associated SNPs drive methylation and expression of NSP genes differently across 
tissues.  
Annotation of the identified variants illustrates their functional potential and highlights the 
importance of using multi-omics data from the same individual, providing insight into the 
plausible mechanistic action of non-coding variants in regulating gene function. For example, in 
the blood-derived DILGOM sample, rs35225704 in ERBB4 was identified both as an eQTL (major 
allele decreases expression, Beta=-0.07) and meQTL (major allele increases methylation at 
cg16329650 (Beta=0.04) but decreases at cg01965462 (Beta=-0.05)). An interplay between 
genotype, methylation and gene expression at this locus is possible, wherein methylation at 
these CpG sites may be the mechanism regulating the observed association between expression 
levels and genotype. 
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We examined differential expression and methylation of the NSP genes between smokers 
and never-smokers. A significant difference in expression of NRG1 and PSEN1 between the two 
groups was observed. Interestingly, pooling occasional smokers with current smokers diluted the 
observed significant difference, suggesting that the NSP expression in occasional smokers 
resembles that of never-smokers. This also highlights the importance of carefully defining 
smoking status (current/regular versus occasional smokers) in gene expression studies. Unlike 
gene expression, no significant differences in methylation of the NSP genes were observed, 
suggesting other mechanisms might be regulating the expression levels.  
As NSP is also implicated in SCZ [117], where patients likely self-medicate by smoking [81], 
we speculated if smoking was confounding the apparent association with the disease. In our small 
sample of SCZ cases and controls, we observed a trend (P-value<0.1) for differential expression 
in NRG1, NRG3, and APH1B which became non-significant when smoking status was included as 
a covariate in the analysis. These results, although not statistically significant (low power), hint 
at confounding the effect of smoking on the NSP expression in SCZ. This has been neglected in 
several studies reporting differential expression of the NSP genes in SCZ (data mined from SZDB 
- Table 6).  
In this study, we demonstrated a thorough examination of the NSP applying a hypothesis-
driven approach. Utilizing in-house and publicly available data, we uncovered potential functions 
of the associations identified. Using a phenotypically rich family sample, we provide support to 
our hypothesis, identifying association between genetic variants in seven of the key NSP genes 
and three distinct phases of smoking behavior - smoking initiation, nicotine dependence and 
nicotine withdrawal. We did not detect any association with alcohol-related phenotypes, 
indicating that this pathway may be specific to smoking and not addiction to other substances, 
although more studies with other illicit substance use are needed to confirm this. Taken together, 
our results illustrate the involvement of the NSP in smoking behavior with several potentially 
functional SNPs which could be probable therapeutic targets for smoking cessation and other 
psychiatric comorbidities. 
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6 Challenges and prospects 
With the advent of technology, disease gene mapping has seen tremendous progress. Earlier 
studies examined only a handful of genetic markers; now high-throughput microarrays are 
common and sequencing technologies are also slowly becoming routine, but we still lack proper 
annotation and interpretation of the findings. GWAS have led to a better understanding of the 
polygenic architecture of complex traits, however, there remain several challenges with regards 
to reaching a clear mechanistic understanding of how complex disease loci influence the 
phenotype. The majority of GWAS hits explain only a small proportion of the total heritability, 
with small effect sizes observed for individual loci, leaving a significant portion unexplained. 
Along with that, the huge burden of multiple hypothesis testing necessitates the need for large 
samples to be analyzed to provide adequate statistical power to implicate any locus. Further, 
since most of the identified associations reside in the non-coding region of the genome, the 
molecular mechanisms by which they might regulate the trait expression remains unexplained.  
Biomarkers, such as metabolites, provide a valuable alternative for objective assessment of 
behavioral phenotypes, given the measurement precision and biological proximity. As they are 
precise molecular measures of trait variance, they provide higher statistical power to capture 
association signals even in smaller samples, as opposed to self-reported phenotypes. For 
example, the difference mentioned by Ware et al. [74] between using cotinine versus cigarettes 
per day in a GWAS provided greater power to identify variants that explain a larger proportion of 
variance in the phenotype. However, large-scale consortia efforts have enabled meta-analyses 
of multiple cohorts, gradually overcoming power issues with self-reported or objectively assessed 
phenotypes identifying more robust associations with precise estimates of effect sizes. This 
approach has worked well for GWAS for over a decade now, but for EWAS, the variation in the 
epigenome due to differences in genetic makeup, lifestyle, environmental exposures, age, the 
tissue being studied, and cellular heterogeneity hinder the analysis and interpretation of results. 
However, EWAS meta-analyses success stories are emerging [142, 153, 229]. With methylation 
studies, identifying whether the association is capturing the phenotype of interest or an 
underlying comorbidity can be challenging. For example, in the recent EWAS meta-analysis of 
educational attainment levels by Linner et al. [229], the association signals overlapped with most 
prominent smoking associated loci. On including smoking as a covariate in their analysis, all 
association signals disappeared (negative correlation between education and smoking [230]); but 
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no such issue was apparent in the GWAS meta-analysis of educational attainment by the same 
consortium [231].  
Among the studies included in this thesis, sample sizes were modest which could have 
resulted in false negatives. In Appendix II, power calculations for the studies included in this thesis 
are included that show we had sufficient power to identify large effects in all three studies but 
modest power to identify smaller effects. While a larger sample size could potentially identify 
additional associations, for study I and II, utilizing biomarkers of nicotine metabolism and nicotine 
exposure allowed us to identify associations in biologically meaningful loci in our samples. The 
family sample utilized in study III is a valuable source for studying substance use disorders given 
its rich phenotype profile capturing a broad range of substance use behaviors. Family samples 
have certain advantages as well as limitations in statistical analysis. While a smaller sample of 
family design is sufficient in identifying rare inherited variants, but at the same time, large 
pedigrees are essential for studying the passage of disease loci. In the NAG-FIN sample, although 
there were 740 families, only a handful of families had large pedigrees. Since at the time of the 
sample collection the mean age of the twins was 57 years, few parents could participate. 
Incomplete family structures or smaller pedigrees may decrease power in family-based analysis. 
However, we used PSEUDOMARKER for joint linkage and LD analysis, which is evidenced to be 
the most powerful tool for family-based analysis [232] and can handle missing parents and 
genotypes. It extracts maximum information from a family sample enabling detection of 
significant associations in seven of the ten NSP genes. The NAG-FIN sample, although ascertained 
for heavy smoking individuals, did not have biochemical verification of the smoking status (unlike 
in study I and II). However, it is unlikely that many non-smokers would have claimed to be 
smokers in the self-report questionnaire; they consistently reported being a smoker in multiple 
follow-ups data collection.  
Several avenues are important for further research to improve interpretation of findings 
from association studies. Using a higher resolution of the genome, integration of multi-omics 
datasets to assess mediation and causality and profiling the omics data in multiple tissues would 
be highly beneficial understanding the variation in traits more extensively. A potential limitation 
of our studies was the use of blood-derived methylation profiles when it is well known that tissue-
specific DNA-methylation profiles exist. Methylation profiles in blood might not be entirely 
representative of tissue of interest, which in our case would have been liver where nicotine is 
primarily metabolized [68] for study I and II, and brain for study III. However, blood is more readily 
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accessible (for clinical purposes as well) and functional than other relevant target tissues. For 
example, blood cells are the first to absorb the effects of smoke exposure in lungs and circulate 
throughout the body. GTEx is an excellent example of cross-tissue expression profiles. More such 
resources, including multiple layers of omics data from the same individual across different 
tissues, could be valuable to the scientific community. It would enable translation of mere 
associations into a clearer picture of functional mechanisms and downstream consequences. 
Adding extra layers of omics data may not be as easy as it sounds. Except for genetic data, other 
omics data may not be stable across time or cell cycle. For instance, expression data in blood is 
not identical at two different time-points at all loci, even if the blood samples have been drawn 
from an individual on the same day.  
Given that most complex diseases are influenced by both genetic and environmental 
factors, to have a full mechanistic insight of how they develop over time would require 
coordinated sets of several omics data at multiple time points, collected from many disease-
relevant tissues. We examined only three of such data layers - genetic, epigenetic and expression 
profiles. There could potentially be many more intermediary mechanisms affecting gene 
regulation which we did not capture. It should also be noted that in this thesis, we have only 
looked at one of the several epigenetic modifiers, DNA methylation. Other epigenetic 
mechanisms may also contribute toward the observed variance in our phenotypes. For example, 
microRNA 101 targets two key genes identified in study II (EWAS on cotinine) - AHRR and CYP2C18 
[233]. The exact mechanism by which this microRNA alters gene activity remains to be elucidated. 
Similarly, exploring the role of other structural genetic variations including ultra-rare SNPs and 
copy number variations might also contribute toward the missing heritability of our phenotypes. 
Causality is difficult to prove but would be greatly informative in understanding disease 
development process and treatment design. Methylation changes that are a consequence of an 
exposure prove to be useful biomarkers, for example, smoking-related methylation changes can 
predict disease risk, like in case of lung cancer [234], Multiple Sclerosis [235] and all-cause 
mortality [236]. Distinguishing methylation changes that lie in the causal pathway from those 
that are a consequence of the disease is crucial for understanding disease etiology. Combining 
genetic and epigenetic data in a causal inference test scenario can be helpful in identifying if 
methylation lies on the causal pathway between the association of a trait and genetic variation. 
We utilized the CIT to assess causal mediation in our studies. CIT works well for assessing 
mediation, as it is based on an initial hypothesis of a causal model (genotype  mediator  
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phenotype; assuming no other causal link between genotype and phenotype) and hence is free 
from problems of reverse causation and confounding [237, 238]. However, the limitation of CIT 
comes from its inability to handle more complex causal models with more than one molecular 
mediator, which might be useful if more biological data layers are available. More flexible 
methods which explore the causal structure from the data after evaluating most plausible 
structures, such as structural equation modeling or Bayesian framework based tools may be 
useful for such scenarios.  
Microarray technology has afforded huge progress in the availability of omics data because 
of its low-cost high-throughput output. However, coverage of the genome with microarray varies 
significantly between different omics layers at present. For instance, genotyping arrays with 
imputation cover ~90% of the genome [239], expression arrays only cover a few exons per gene, 
and the methylation array used in this thesis (450k) covers ~1% of the CpG sites in the human 
genome. Such inconsistent coverage resulting in an incomplete and biased view of the relative 
contribution of genetic and epigenetic factors to trait variation may be a limitation such that not 
all disease-relevant loci can be identified. Sequencing technology, for example, whole genome 
sequencing for genetic data, RNA-seq for expression data and whole-genome bisulfite 
sequencing for methylation data would provide a much higher resolution into the genome. 
Although implementing all these newer technologies to dig deeper into the genome hold 
promise, they come with additional costs and the added burden of multiple hypothesis testing. 
It is a matter of what the research question is, screening versus targeting a region in a magnified 
fashion. Other enhancement avenues using microarrays include the use of population-specific 
imputation reference panels [240] for genotype data and higher coverage EPIC array (the 
successor of the 450k) for methylation data.  
Studies included in this thesis were performed in Finnish population samples. Finnish 
population, a genetic isolate, has already proven extremely useful for mapping genes involved in 
rare monogenic disorders [241] but also suggests that the results may be specific to Finnish 
population. This supports the idea of designing personalized treatments. For instance, genetic 
data can be used to determine the efficacy of a drug/medication or its dosage, possibly 
preventing adverse drug responses and in-turn saving costs for treatment facilities. Such genetic 
profiling was tested in a clinical trial to examine efficacy of smoking cessation treatments [105]. 
Participant’s nicotine metabolism rate was characterized using a genotype-based metric (CYP2A6 
alleles [242, 243]) and the results indicate that slow metabolizers do not benefit from active 
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treatment (nicotine replacement therapy, bupropion, or combination) compared to placebo, 
while normal or fast metabolizers benefit significantly [105]. This means individuals with 
genetically determined slow nicotine metabolism rate, can avoid taking ineffective treatments 
and potentially their toxic effects. Such patient-specific prescriptions may also benefit from the 
use of other omics data, thereby leading to a more accurate medication prescription and dosage 
tailored to individual patients. Candidate pathways and genes and/or their downstream targets 
also present potential targets for smoking cessation aid [244] and smoking comorbid psychiatric 
illnesses. For instance, downstream targets of the NSP are being evaluated as drug targets in SCZ 
[245, 246]. Epigenetic alterations represent new vistas for therapeutic development and selective 
manipulation of epigenetic marks such as methylation in genes like CYP2A6 and CYP2C18 
involved in metabolism of xenobiotics hold high potential [247]. It is only once causal genes are 
identified that designing personalized therapeutics comes into picture. Actual translation of the 
identified loci into tangible targets remains a major challenge in solving the complex puzzle of 
smoking.   
Conclusion 
52 
 
7 Conclusion 
One of the key avenues in public health is the identification of modifiable factors that 
causally influence disease risk. Owing to the adverse health effects of nicotine and tobacco, 
understanding the consequences and mechanisms involved in nicotine exposure are crucial. With 
technological advancements, we can dig deeper into the genome and identify susceptibility loci 
implicated in complex traits. Identifying and characterizing the contribution of disease-risk 
associated variants is crucial in taking healthcare toward personalized medicine. The findings 
presented in this thesis are centered on the theme of genetic and epigenetic alterations affecting 
smoking behavior via genes involved in nicotine metabolism, nicotine dependence, and neuronal 
pathways.  
Study I and II showed the utility of a hypothesis-free scan of the genome using biomarkers 
of smoking, revealing genetic loci involved in nicotine metabolism and epigenetically regulated 
smoking-related genes. In both studies, an interplay between the genome and epigenome, and 
evidence of methylation causally mediating some of these effects was noted. Probable 
downstream effects of identified associations were examined through the integration of multi-
omics datasets. These two studies also highlight the benefit of using a biomarker as a phenotype, 
providing greater statistical power as well as biological proximity to the exposure, in identifying 
relevant loci for behavioral traits. In study III, using a targeted approach we validated the role of 
neuregulin signaling pathway specifically in smoking behavior and highlighted functional 
potential in most of variants identified through integrative analysis of multi-omics datasets. Our 
results also suggest confounding effects of smoking should be taken into consideration for gene 
expression studies, especially for highly comorbid disorders like schizophrenia.  
In conclusion, the work presented in this thesis provides insight into the association and 
interplay of genetic and epigenetic variants that influence the complex trait of smoking behavior. 
Further, using multiple biological data layers the regulatory potential of seemingly non-functional 
trait associated variation was assessed. Our findings suggest that the genome and the epigenome 
act in concert and methylation may be a molecular mechanism mediating the observed effects 
in some genes. The research produced in this thesis is not only relevant for public health but also 
highly crucial for meeting the bigger goal of making the world nicotine and tobacco free. It opens 
a window of opportunity in genomics-based personalization of pharmacotherapeutics for 
enhanced smoking cessation and treatment of comorbid disorders.   
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Appendix II 
Power Calculations 
Study I: We estimated the power of our GWAS meta-analysis sample to detect signals at the P-
value<5E-8 significance threshold assuming an LD (r2) of 0.8 between the causal allele and the 
marker allele. We used the Genetic Power Calculator [248] to estimate the power. 
  MAF 
0.01 
MAF 
0.03 
MAF 
0.05 
MAF 0.1 MAF 0.2 MAF 0.4 
Beta ±0.1 0.00% 0.00% 0.00% 0.00% 0.02% 0.11% 
Beta ±0.2 0.00% 0.01% 0.04% 0.58% 6.17% 25.61% 
Beta ±0.3 0.00% 0.16% 1.20% 14.72% 66.79% 96.23% 
Beta ±0.4 0.02% 1.71% 11.75% 66.79% 99.25% 100.00% 
Beta ±0.5 0.13% 10.02% 45.53% 97.32% 100.00% 100.00% 
Beta ±0.6 0.56% 33.02% 83.38% 99.97% 100.00% 100.00% 
Beta ±0.7 2.03% 65.72% 98.02% 100.00% 100.00% 100.00% 
Beta ±0.8 5.94% 89.50% 99.92% 100.00% 100.00% 100.00% 
According to the power analyses we had inadequate power to detect signals with rare SNPs (MAF 
<5%) unless they have very large effect sizes, but high power to detect signals with common SNPs 
(MAF >5%) that have medium to high effect sizes (Beta>±0.6). 
Study II: Using the G*Power tool [249], we performed post-hoc power analysis with a significance 
level of 0.05 and sample size of 310, we have high power to detect large effects (0.3-0.05), 
however, we have low power to detect smaller effect sizes (~0.001). 
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Study III: Similar to study I, we estimated the power of our association discovery sample (NAG-
FIN; N=1998) to detect signals at the 3.5E-04 significance threshold (equivalent to FDR adjusted 
P-value=0.05) assuming an LD (r2) of 0.8 between the causal allele and the marker allele using 
the Genetic Power Calculator [248]: 
  MAF 
0.01 
MAF 
0.03 
MAF 
0.05 
MAF 
0.1 
MAF 0.2 MAF 0.4 
Beta ±0.1 0.13 % 0.45 % 0.96 % 3.02 % 9.47 % 21.11 % 
Beta ±0.2 0.71 % 5 % 13.38 % 42.94 % 83.14 % 97.65 % 
Beta ±0.3 2.96 % 24.87 % 55.09 % 93.7 % 99.94 % 100 % 
Beta ±0.4 9.28 % 61.41 % 91.45 % 99.94 % 100 % 100 % 
Beta ±0.5 22.38 % 89.64 % 99.55 % 100 % 100 % 100 % 
Beta ±0.6 42.27 % 98.73 % 99.99 % 100 % 100 % 100 % 
Beta ±0.7 64.45 % 99.93 % 100 % 100 % 100 % 100 % 
Beta ±0.8 82.56 % 100 % 100 % 100 % 100 % 100 % 
 
Our discovery sample had adequate power (>80%) to detect variants with MAF>0.05 and medium 
to large effect sizes (Beta>±0.5), and low power to detect variants with MAF<0.01 with similar 
effect sizes.  
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